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SUMMARY
This thesis reviews blood rheology and its known associations with 
diabetes mellitus and vascular complications in diabetic patients. The 
relationship between blood viscosity and two conditions which are common 
in diabetes, namely hypertension and peripheral neuropathy, was 
examined for the first time. Type 2 (non-insulin dependent) diabetics with 
hypertension were found to have increased blood viscosity compared with 
normotensive type 2 diabetics. Blood viscosity and red cell deformability 
were measured in diabetic patients with peripheral neuropathy. When 
compared with diabetics who have no evidence of neuropathy but were 
matched for other microvascular complications , no differences were found.
Using the recently-introduced Carri-Med filtrometer, red cell deformabiltiy 
was assessed by filtration through Nuclepore membranes in a large group 
of type 1 (insulin-dependent) and type 2 diabetic patients. Compared with 
healthy control subjects, deformability was impaired in all diabetic patients, 
but to a greater extent in type 1 patients. In the control population, red cell 
filterability was related to mean cell volume; while in diabetic patients, it 
was related to mean cell haemoglobin concentration. Within the diabetics, 
red cell filtration was not significantly different in patients with microvascular 
or macrovascular complications.
Red cell aggregation was measured in the new Myrenne photometric 
aggregometer and found to be increased in both type 1 and type 2 diabetic 
patients, particularly hypertensive type 2 diabetics. Aggregation was found 
to be related to plasma triglyceride and very low density lipoprotein levels.
17
Deformability of white cell subpopulations was measured by a filtration 
method in type 2 diabetics, and although non significant differences were 
found when compared with non-diabetic control subjects, a correlation of 
both mononuclear and polymorphonuclear cell filtration pressure was 
demonstrated with glycaemic control.
The implications of the findings in these studies are discussed, and 
suggestions for further rheology studies in diabetic patients are proposed.
18
CHAPTER 1 
BLOOD RHEOLOGY
19
1.1 Introduction
Rheology is the study of deformation and flow of matter, and 
haemorheology is the study of deformation and flow of blood (1). Blood 
flow depends on the pumping action of the heart, the resistance to flow 
imposed by the blood vessels and the resistance to flow of the blood itself. 
Blood flow, therefore can be altered not only by diseases of the heart or 
blood vessels but also by abnormalities of the constituents of the blood.
Blood is basically a suspension of red and white cells and platelets in 
plasma, and plasma is a suspension of proteins and smaller molecules in 
water. Macrorheology describes the flow of blood as a bulk fluid, and 
microrheology the flow of individual cells.
Shearing within a liquid is the telescopic sliding of theoretical "layers" over 
each other (streamlines) and shear stress is the force required per unit area 
to cause shearing, while shear rate is the velocity gradient between 
adjacent layers. The shear rate is determined by a dynamic interaction of 
flow rate and vessel radius, and mean shear rate can be determined by the 
equation :
Mean shear rate (s"1) = 4 x Velocity (m/$^
Radius (m)
The viscosity of a liquid (r|) is the measure of its resistance to flow and is 
defined as the ratio of shear stress (x) to shear rate (y):
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Viscosity (mPa.s) = Shear stress (mPa)
Shear rate (s_1)
Thus as the viscosity of a liquid increases, a greater force is required to 
achieve the same shear rate and flow rate.
Sir Isaac Newton's hypothesis (1686) stated that fluids had a constant 
viscosity at constant temperature i.e. the shear rate was directly 
proportional to the shear stress. This certainly holds true for fluids such as 
water and plasma and these are therefore known as Newtonian fluids. 
However whole blood viscosity is dependent on the shear conditions and 
blood is therefore Non-Newtonian (2). The relationships between shear 
rare and viscosity for plasma and blood are shown in Figure 1.1.
1.2 Interaction of flow conditions and blood rheology
The flow rate of a liquid is inversely related to its viscosity and is directly 
related to driving pressure. In a straight tube, the length and radius of the 
tube determine resistance to flow. The Hagen-Poiseuille equation shows 
the relationship between these variables:-
Flow rate a pressure gradient x tube radius 4 
tube length x fluid viscosity
In the circulation, blood flows along an energy gradient from high energy, 
high flow rate arteries to the low energy, low flow rate venous system, and 
its rheological behaviour depends not only on flow conditions but also on 
its viscosity, which is determined by frictional interactions between its
21
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Figure 1.1
Dependence of blood viscosity on shear rate. Normal blood 
shows non-Newtonian behaviour, with a marked increase 
in viscosity at low shear rates. Plasma and water are 
Newtonian fluids, i.e. they show no shear dependence.
component parts, i.e. the cells and plasma. Blood flow to an organ 
therefore depends on the driving blood pressure gradient, the vascular 
resistance of the vessel and the viscosity of the blood.
Abnormalities of vascular resistance can be encountered in both the arterial 
and the venous circulation: stenosis due to atherosclerosis, 
thromboembolism, spasm or arteritis will increase arterial resistance, while 
venous thrombosis and increased tissue pressure which collapses veins 
will increase venous resistance. Because low flow rates increase blood 
viscosities, rheological factors will probably be of greater importance in the 
presence of any of these vessel abnormalities, or in the presence of a 
generalised fall in driving pressure e.g. in circulatory shock.
1.3 Rheological factors
The determinants of blood viscosity include the plasma viscosity, the 
volume ratio of cells to plasma (determined by red cell count and red cell 
volume), and by other properties of the cellular constituents.
1.3.1 Plasma Viscosity
The viscosity of plasma is about 1.6 times that of water, because the flow 
streamlines of plasma water are being interrupted by large plasma proteins 
such as fibrinogen and globulins (3,4). Fibrinogen is one of the largest and 
the most asymmetrical of the plasma proteins, and thus has an important 
effect on viscosity despite a lower concentration than either serum globulins 
or albumin. Serum globulins in turn have a greater effect than albumin, 
although again lower in concentration, (Table 1.1). The general 
composition of plasma is shown in Table 1.2. The viscosity of plasma is
22
Table 1.1
Contribution of plasma proteins to the increase of the mean 
normal plasma viscosity over the viscosity of water.
'(/)
oow
> Characteristics of protein molecules
o ~
t) Molecular Molecular dimensions (A)
&  weight ; ~  —
lu  Length Diameter L/D ratio
*  (L) (D)
Protein 78 99
Albumin 45 58 36 69000 150 38 3.95
Globulin 30 38 41 160000 235 44 5.34
Fibrinogen 3 3.8 22 341000 700 38 18.4
Non-proteins
(From Harkness J. Measurement of plasma viscosity.
In Lowe G D 0 , Barbenel J C, Forbes C D. Eds.
Clinical aspects of blood viscosity and cell deformability. 
Berlin: Springer-Verlag 1981 ;79)
Table 1.2
The protein and lipid constituents of plasma
molecular molecular 
concentration weight dimensions 
Material (g/dl) x103 (nm)
proteins:
Albumin 3.3-5.0 69 15x4
a-j - globulins 0.31 -0.32 44 -200
a 2 - globulins 0.48-0.52 150 -300
p - globulins 0.78-0.81 90 -1300
Y - globulins 0.66-0.74 160 -320 23 x4
Fibrinogen 0.20-0.43 400 50-60x3-8
Cholesterol 0.14-0.27 0.39
Triglyceride 0.002-0.015 0.9
VLDL 50
LDL 21
HDL 12
(Modified from Caro C G, Pedley T J, Schroter R C, Seed W A. 
The mechanics of the circulation. Oxford: University Press 1978.)
independent of shear rate i.e. it is Newtonian (3) and can be measured in 
capillary viscometers by using the Hagen-Poiseuille equation. In 
pathological states, where there is an increase in large asymmetrical 
plasma proteins (e.g. paraproteinaemia) the plasma viscosity will be 
increased, as will the whole blood viscosity because the viscosity of the 
suspending medium (plasma) contributes to the viscosity of the suspension 
(blood). Plasma viscosity exhibits a degree of shear rate dependence in a 
few cases of paraproteinaemia, due to complexing of paraproteins (5).
1.3.2 Whole Blood Viscosity
When erythrocytes, which constitute the largest percentage of blood cells, 
are added to plasma, the whole blood viscosity increases logarithmically 
with a linear increase in packed cell volume (6). To determine if differences 
in blood viscosity are due to factors other than haematocrit (Hct), viscosity 
at a standard haematocrit (0.45) can be calculated from the following 
equation (7):
0.45 
native Hct
Blood viscosity (Hct 0.45) _ r Blood viscosity (native Hct) ,
Plasma viscosity L Plasma viscosity J
Whole blood viscosity is haematocrit dependent at any shear rate. At high 
shear rates, deformation of erythrocytes into ellipsoids allows them to 
become orientated in parallel with flow streamlines, thereby reducing the 
bulk viscosity (8). At shear rates of greater than 50/s the cell membrane 
may exhibit a "tank-treading " motion around the cytoplasm and it has been 
suggested that this could also reduce the suspension viscosity (9). At low 
shear rates, shear deformation of erythrocytes is reduced and erythrocytes
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are joined by plasma protein bridges, (which overcome their natural 
electrostatic mutual repulsion) to form linear aggregates causing disruption 
of the flow streamlines and increasing bulk viscosity (10).
The determinants of blood viscosity are therefore plasma viscosity, 
haematocrit, red cell deformability and red cell aggregation. The 
contribution of cell deformation and aggregation to the rheological 
behaviour of blood may be estimated by calculation of relative blood 
viscosity, which is the ratio of blood viscosity at a standard haematocrit to 
plasma viscosity:
relative viscosity = whole blood viscosity (45% hctl 
plasma viscosity
At high shear rates, relative viscosity is a measure of the degree by which 
red cells elevate plasma viscosity due to lack of deformation. At low shear 
rates, relative viscosity is a measure of the degree by which red cells 
elevate plasma viscosity due to aggregation.
The relationships between blood viscosity, shear rate, red cell deformation 
and red cell aggregation and viscosity are shown in Figure 1.2. Fibrinogen 
depletion reduces red cell aggregation and hence low shear viscosity. 
Hardening of cells with aldehydes reduces their deformability and 
aggregation and abolishes shear dependence.
The viscosity of all fluids is temperature dependent, an increase in 
temperature resulting in decreased molecular interactions and hence in 
decreased viscosity. This temperature dependence is seen in both plasma 
and whole blood viscosity (11)
24
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The effects of red cell aggregation and red cell deformation 
on the shear dependence of blood viscosity
1.4 Red cell deformability
In the resting state erythrocytes are biconcave discs with a diameter of c. 
7.5pm. Deformation is important in the macrocirculation because it 
contributes to the low bulk viscosity of blood at high shear rates, and also in 
the microcirculation where this property allows the cells to traverse nutritive 
capillaries (mean diameter 3-5pm). The excess surface area to volume 
ratio of biconcave erythrocytes facilitates deformation, and conditions in 
which this ratio is reduced (e.g. spherocytosis) result in a reduction of red 
cell deformability (12). Transformation of cells to alternative shapes (such 
as stomatocytes) by chemical stresses will also cause a loss of 
deformability (13). The other main determinants of deformability are cell 
age, (older cells are less deformable than younger cells (14)), cell 
membrane fluidity (15), internal viscosity - determined largely by the mean 
cell haemoglobin concentration, MCHC (16); and cell size i.e. mean cell 
volume (MCV), the deformability being reduced by increased MCV (16, 17).
The intracellular fluid viscosity increases non-linearly with increasing cell 
haemoglobin concentration and thus the deformability falls (13). Abnormal 
haemoglobins (eg in sickle cell disease) are also associated with increased 
intracellular viscosity for a given haemoglobin concentration (18, 19).
The red cell membrane consists of a phospholipid bilayer matrix. Lecithins 
and sphingomyelins are on the outside and phosphatidyl 6-ethanolamines 
and phosphatidylserine lipids on the inside. The proteins spectrin, actin 
and band 4.1 on the surface provide mechanical strength in the membrane. 
Within the lipid bilayer the ratio of cholesterol to phospholipid has an 
important control on fluidity (20, 21). Changes in this lipid bilayer or in 
protein structures will affect membrane microviscosity, which will increase
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the resistance to deformation and impair shape recovery after deformation 
(22).
1.5 Red cell aggregation
At low shear rates normal erythrocytes aggregate to form rouleaux which 
disturb flow streamlines and cause an increase in whole blood viscosity. 
Aggregation of cells is reversibly dependent on the cell to cell protein 
bridges (23) which are created by large plasma proteins such as fibrinogen 
and a 2-macroglobulin (24). These proteins are absorbed to the cell 
surface and are capable of overcoming the natural repulsive forces of the 
negatively charged red cells (25,26). The exact binding forces are 
unknown but may be due to hydrogen bonding (van der Waal's attraction) 
(27). The paraproteinaemias are associated with an increase in both 
plasma viscosity and red cell aggregation, due to production of abnormal 
globulins.
An increase in haematocrit up to 40 to 50% will also increase aggregation, 
but at very high haematocrits the close proximity of the cells reduces 
aggregation (24). At normal haematocrit and plasma protein levels, 
aggregates are easily dispersed by an increase in shear stress (23), the 
cells become orientated and deformed in the direction of the flow 
streamlines. Other factors which exert an influence on red cell aggregation 
are cell size and age: the older and smaller the cell the greater the degree 
of aggregation (28), and the rigidity of the cell - increased rigidity being 
associated with reduced rate of aggregate formation (29).
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1.6 White cell deformability
White blood cells are less in number than red blood cells by a factor of 
about 700, they have similar diameters to red blood cells (6.2-7.5 pm) but 
due to their spherical shape have twice the volume. Their spherical shape, 
increased internal viscosity (about three orders of magnitude higher than 
red cells), and reduced elasticity render them less deformable than red 
cells (30). White cell subpopulations differ in their rheological properties, 
with monocytes being the least deformable followed by polymorphonuclear 
cells and lymphocytes (31,32).
White blood cells contribute little to the bulk resistance of blood to flow in 
the macrocirculation, but it is in microcirculatory blood flow that their poor 
ability to deform is most important, since they have greater difficulty entering 
and traversing nutritive capillaries. At low shear rates in small diameter 
vessels, white cells can cause a transient arrest in blood flow and red cells 
will tend to build up behind these impacted cells thus increasing viscosity 
by increasing red cell aggregation (33). The flow of other white cells 
becomes marginal in venules, which will facilitate their adherence to the 
endothelial surface, reducing venular diameter and causing a further 
increase in flow resistance (34).
1.7 Platelet aggregation
The small diameter of platelets (2-4 pm) means that they have negligible 
effects on bulk viscosity. However aggregation of platelets and adhesion of 
such aggregates to vascular subendothelium (e.g. at arterial stenosis) 
alters blood flow. High haematocrit levels and high shear rates cause
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diffusion of platelets towards the vessel wall (35), thus facilitating adhesion 
(36). Increased red cell volume (37) and decreased red cell deformability 
(38) increase platelet adhesion. Shear induced release of adenosine 
diphosphate (ADP) from red cells causes platelet activation which in turn 
results in increased platelet aggregation, and such release of ADP may be 
increased by reduced red cell deformability (39).
1.8 Flow conditions and blood rheology in disease
1.8.1 Macro vascular disease
Flow separation areas (e.g. bifurcations) are associated with low shear 
rates (40), as are the axial regions of large vessels (41). These areas allow 
accumulation of red cell aggregates. Flow separation areas are also the 
sites at which lipids may accumulate and predispose to atherosclerosis, 
leading to stenosis. Stenosis formation will also increase shear stresses 
upon the blood as it passes through and thus activate platelets and 
enhance the formation of thrombi. Red cell aggregation will significantly 
increase blood viscosity at low perfusion pressures causing low shear 
conditions, thus reducing blood flow.
1.8.2 Micro vascular disease
Vessel radius, determined by vascular morphology, is the most important 
factor controlling blood flow to an organ according to the Hagen-Poiseuille 
equation. Abnormalities of microvessels may not only have a direct 
adverse effect on microrheology, but also when combined with a primary
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rheological abnormality there will be further compromise to an organ's vital 
blood flow.
Red cell aggregation is least likely to occur in the capillaries due to their 
narrow geometry, high shear rates and low haematocrit (F&hraeus effect), 
(42), thus maintaining a low viscosity. It is in the low shear environment of 
the post-capillary venule that red cell aggregation influences flow in the 
microcirculation; an increase in viscosity in the post-capillary venule due to 
red cell aggregation will increase capillary back pressure, promote fluid 
transudation and haemoconcentration, and reduce flow (43). This effect on 
blood viscosity will be enhanced by elevated levels of haematocrit or 
plasma proteins which favour red cell aggregation.
The high shear forces existing in normal capillaries (Figure 1.3) aid the 
deformation of the red cell, thus facilitating its passage through the narrow 
organ capillaries for oxygen delivery. Narrowing or occlusion of these 
capillaries will impede red cell flow and may lead to ischaemic organ 
damage.
In high flow states in the arterioles, the red blood cells tend to flow axially, 
displacing white cells peripherally and when white cells reach the nutritive 
capillary first, they will raise the local resistance and cause preferential 
entry of red cells into other capillary branches. Hence white cells exert a 
significant influence on microcirculatory flow of red cells (44). Alterations in 
deformability of red or white cells leading to impaired entry to the capillary 
will have important effects on tissue oxygen delivery.
In low flow states in post-capillary venules, red cell aggregation results in 
white cells being pushed towards the vessel wall which facilitates leucocyte 
adhesion and further narrowing of the vessel lumen with reduction in 
vessel conductivity (33).
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Art - arterioles 
Cap - capillaries 
Ven - venules
Variation in the parameter 4v/r in various parts 
of the circulation.
Diabetes mellitus is classically associated with altered microvessel 
geometry, and thus studies of blood rheology are of particular significance 
in this condition.
1.9 Review of methodology for measuring blood rheology
1.9.1 Blood viscosity
a) Capillary viscometers: These instruments are relatively simple and 
consist of tubes through which a column of liquid is passed, which is 
sheared by flow past the wall of the tube. A constant pressure is usually 
applied e.g. the standard height column of the liquid in the Ostwald (U- 
shaped ) viscometer (3), the flow rate is calculated, and viscosity estimated 
from the equation:
b) Semi-automatic capillary viscometers: These are more sophisticated 
instruments and have standardised capillary dimensions, constant driving 
pressures and accurate temperature control e.g. the Coulter-Harkness 
viscometer (45). These viscometers are commonly used for plasma or 
serum viscosity measurements, but can also be used for measuring whole 
blood viscosity at high shear rates
viscosity = APx r4 
Q x L x 8
AP=pressure gradient 
r=tube radius 
Q=flow rate 
L=tube length
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c) Rotational viscometers: Here the test liquid is sheared between two 
closely adjacent, concentric surfaces (one fixed, the other moving 
rotationally). This creates a uniform shear rate, across the test fluid which 
can not be achieved in a capillary tube and, rotational viscometers are 
therefore useful for non-Newtonian fluids such as whole blood. In these 
viscometers the rotational shear is usually calculated from the torque 
measurement and the shear rate is pre-set by choosing the rotational
speed, hence the viscosity can be determined (rj = x/y). There are a 
number of different rotational viscometers available. The cone-plate variety 
e.g.Wells-Brookfield, consists of a cone which is rotated on the surface of a 
flat plate with the fluid lying in between (46). The cone applies the shear 
and also measures the torque. In the cone-in-cone variety the fluid is 
placed between the two cones, and the torque exerted on the inner cone is 
measured optically (47). Coaxial or couette viscometers consist of a 
cylindrical cup in which a bob is suspended (the fluid lies between bob and 
cup), and the torque measured electromagnetically. These viscometers are 
useful for measuring viscosity accurately at both high and low shear rates 
e.g. the Contraves LS 30 viscometer (48). Finally the controlled stress 
rheometer utilies the principle of varying the shear stress and measuring 
the shear rate, which may be a more physiological approach e.g. the Carri- 
Med CS viscometer (49).
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1.9.2 Red cell deformability
a) High shear viscometry: After correcting for the effects of haematocrit and 
plasma viscosity (e.g. calculating relative high shear viscosity), high shear 
viscometry can be used as an indirect measure of bulk red cell 
deformability. Red cell suspensions can also be studied. This method 
however can not be used to estimate red cell deformability in the 
microcirculation, where red cells deform individually. Filtration methods are 
preferred for this purpose.
b) Bulk filtration: This involves the filtration of large numbers of red cells 
through micropores, usually 3-5 pm in diameter, and is a more direct 
method of measuring the ability of the cell to adapt and pass through 
channels of a similar size to those encountered in the capillary 
microcirculation in vivo. In general the flow rate of the cells is estimated 
and expressed relative to the flow rate of buffer. Cells can be filtered 
through the membrane by positive pressure e.g. in the Erythrometre (50), 
by gravity e.g. in the Hemorheometre (51) or by negative pressure e.g. the 
Carri-Med filtrometer (52). Using these instruments, the white cells and 
platelets usually have to be reduced in number to prevent clogging of the 
filters. However in the Carri-Med filtrometer extrapolation of the clogging 
rate to calculate the initial flow rate is insensitive to residual leucocytes (52).
c) Red cell subpopulations: It can be argued that it is preferable to measure 
the ability of individual red cells to deform. This normally involves the 
examination of single cells e.g. in micropipettes. These usually have a tube 
diameter of 3-5 pm and the pressure changes required to oscillate the cell 
can be measured (53). If smaller diameter tubes are used, then the 
deformability of the membrane alone can be measured. The single
32
erythrocyte rigidometer is a varient on the filtrometers described above, and 
estimates the time taken for individual cells to pass through a single pore in 
a plastic membrane of 5-6pm diameter (54). Another apparatus, the Cell 
Transit Time Analyser, has recently been developed, which uses a 20-pore 
membrane.
The main disadvantages of these filtration techniques are lack of 
standardisation, large variability and sensitivity to mean cell volume 
especially with 3 pm pores. They may be used to study cell fractions, e.g. 
by density gradient separation old and young cells can be examined 
separately.
d) The ektacytometer is a unique instrument which measures red cell 
elongation at a standard shear stress but changing osmolality, so that not 
only can membrane rigidity be estimated, but the effects of mean cell 
haemoglobin concentration and cell surface area / volume ratio can be 
taken into account (55).
1.9.3 Red cell aggregation
a) Low shear viscometry: An indirect estimation of red cell aggregation can 
be made from measuring relative blood viscosity at low shear rates.
b) Ervthrocvte sedimentation rate: This is a very simple way of estimating 
aggregation, by measuring the descent of the red cell column in whole 
blood with time. Its main disadvantages being that it is sensitive to both age 
of the sample and haematocrit.
c) Direct microsnnpic observation: This is the most direct way of measuring
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red cell aggregation, but is tedious and poorly standardised. An indexing 
system can be used to measure the average size of rouleaux (56).
d) RhQQ$Qppy: This consists of a cone-plate viscometer with attached 
microscope, which shears the sample at high shear rates. After stopping 
rotation, the rate of rouleaux formation can be observed, as can the size of 
the aggregates and resistance to shear stress (57).
e) Photometry: This employs the principle that there is increased light 
transmission through areas of cell free plasma when the red cells 
aggregate. The erythrocyte aggregometer (Myrenne) is a new apparatus 
which is a highly automated cone-plate viscometer, which again shears the 
blood at high shear rates and measures the degree of aggregation over 
time after stopping rotation (58).
1.10 Summary
In recent years more attention has been focussed on the individual 
determinants of blood viscosity, and their influence on blood flow. 
Abnormal rheology may not only contribute to vascular complications in 
certain disease states (e.g. paraproteinaemias) but also in combination with 
blood vessel abnormalities may present additional flow impairment leading 
to ischaemic organ damage. Although much is known about bulk blood 
rheology, and macrorheology can be adequately determined using current 
viscometers, the measurement of microrheology is influenced by 
individual cellular properties and a wide variety of techniques is currently 
used. The newer instruments require further evaluation, in particular the 
Carri-Med filtrometer for measuring red cell deformability, and the
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Erythrocyte aggregometer for measuring red cell aggregation. There is 
also a need to develop systems for measuring white cell deformability 
because despite their relatively small number compared to red cells, further 
impairment of their normally poor deformability could have a greater 
potential for disturbing flow in the microcirculation.
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CHAPTER 2 
BLOOD VISCOSITY IN DIABETES MELLITUS
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2.1 Introduction
Diabetes mellitus is a common disorder which affects about 1% of the 
population. It is generally divided into two basic types, although it may be 
the consequence of other acquired or genetic diseases. Both types of 
diabetes have similar symptoms and signs at presentation and are 
associated with similar long-term complications but have quite distinct 
aetiologies. Type 1 diabetes, also known as insulin-dependent, ketosis- 
prone or juvenile onset diabetes, is associated with HLA- DR3 and -DR4 
haplotypes (59) and is thought be be the result of islet cell destruction by 
autoantibodies (60). Affected individuals tend to develop diabetes in 
childhood or young adulthood. These diabetics therefore have insulopenia 
and eventually have no endogenous insulin secretion. Type 2 diabetics , 
also known as non-insulin-dependent, non-ketosis-prone, or maturity onset 
diabetes, on the other hand are older, usually overweight and often have 
high insulin levels, especially at the onset of diabetes (61). The 
hyperinsulinaemia is associated with a degree of insulin resistance and 
insulin-receptor down-regulation (62), although eventually insulin secretion 
may fall and in some cases treatment with exogenous insulin is required. 
This type of diabetes is familial and is the commoner of the two basic types 
by a factor of 4 :1.
Diabetes is associated with several specific complications due mainly to 
disturbance of the microcirculation, namely retinopathy and nephropathy, 
and neuropathy which is generally assumed to have a metabolic origin. 
However all microvascular complications have been related to both 
duration of disease (63) and to glycaemic control (64), and as a 
consequence of the former, type 1 diabetics are obviously more prone to 
these complications.
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Macrovascular disease i.e. ischaemic heart disease, cerebrovascular 
disease and peripheral vascular disease are all commoner in diabetic 
patients (65), both type 1 and type 2, but due to the greater age of the type 
2 patients large vessel disease tends to be more prevalent in this group.
2.2 Complications in diabetes mellitus
2.2.1 Microvascular
2.2.1 (i) Retinopathy
Diabetic retinopathy rarely develops before 10 years duration of diabetes, 
but in type 2 diabetics may present apparently before this time due to the 
condition being undiagnosed for several years. Generally speaking, after 
about 5-20 years duration of diabetes the prevalence of diabetic 
retinopathy is about 67-100% (66,67).
In health a blood-retinal barrier exists, formed by the tight junctions 
between endothelial cells (68). In diabetic patients this barrier is imperfect 
due to various mechanisms (69); one of the capillary abnormalies is 
endothelial cell proliferation which may contribute to breakdown of the 
blood-retinal barrier (70). Basement membrane thickening in capillaries is 
a widespread feature of diabetes (71), thought to be due to augmentation of 
the membrane by entrapped plasma proteins after leakage through the 
endothelial cell junctions (70). Other suggested mechanisms contributing 
to endothelial damage include reduced prostacyclin activity (72) and 
reduced fibrinolytic activity (73).
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The cause of retinopathy is unknown but the clinical manifestations are due 
to vascular occlusion i.e. non-perfusion leading to ischaemic 
haemorrhages and neovascularisation and ultimately in some cases a 
degree of visual loss. The initial lesions consist of microaneurysms, "dot 
and blot" haemorrhages and hard exudates - this is known as background 
retinopathy. In many patients there is little progression beyond this stage 
but others develop ischaemic or pre-proliferative retinopathy. This is 
characterised by large blotch haemorrhages, soft exudates (cotton-wool 
spots) and venous abnormalities such as beading and the formation of 
loops. Fluorescein angiography shows capillary non-perfusion. New 
fragile capillaries develop in the areas of occlusion in response to release 
of retinal vasoproliferative factors and are liable to rupture and cause 
vitreous haemorrhage.
2.2.1 (ii) Nephropathy
Diabetic renal disease is the other main manifestation of microvascular 
disease in diabetes. It affects about 25% of all diabetics after 15-25 years 
duration of disease (74), thereafter the risk appears to be reduced 
presumably due to protective genetic factors (75).
The underlying pathological lesion in diabetic nephropathy is 
glomerulosclerosis (76). As in retinopathy basement membrane thickening 
of the glomerulus occurs in diabetes (77). This is thought to be due to 
defective removal of basement membrane in addition to entrapment of 
plasma proteins and leads to their accumulation in the mesangium (78). 
The changes in the glomerulus lead to increased permeability and protein 
loss. Other contributing factors may be fibrin deposition (79), and leakage 
of plasma collagenase inhibitors (80,81).
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The first clinical sign is an intermittant increase in microprotein excretion 
detected in the urine. This becomes more persistent and the degree of 
protein excretion increases until the stage of macroproteinuria. This stage 
may last for years and since renal function is preserved patients are usually 
asymptomatic. Progression to renal failure is variable thereafter and can 
again be very slow; the serum creatinine rises, oedema and hypertension 
develop, and the serum albumin level falls. Although end-stage renal 
failure may be treated with dialysis or transplantation the main cause of 
death in these patients is from arterial disease (82).
2.2.1 (iii) Neuropathy
Both the somatic and automatic nervous systems may be involved in 
diabetes mellitus. The commonest form of somatic neuropathy is a 
peripheral sensorimotor neuropathy affecting the limbs in a "glove and 
stocking" distribution with the legs being predominantly affected. The true 
prevalence of this condition is difficult to establish because several studies 
have shown that patients may have neurophysiological or clinical evidence 
of neuropathy but are asymptomatic (83) and conversely some studies 
have shown that many patients with symptoms have no evidence of 
neuropathy on conventional testing (84). Prevalence certainly increases 
with age and duration of disease being about 50% after 25 years (63).
Diabetic neuropathy is often worse during periods of poor control and this 
has led to the assumption that the aetiology is mainly metabolic; possibly 
due to intraneural accumulation of sorbitol and fructose from increased 
polyol pathway activity (85) or reduced levels of myoinositol (86). Isolated 
nerve lesions occur in diabetes and are thought to have a focal ischaemic 
cause (87), and because the prevalence of neuropathy tends to follow that 
of other microvascular complications it has been suggested that micro
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vascular lesions may contribute to diabetic peripheral neuropathy (88).
Patients with peripheral neuropathy present with a variety of symptoms 
including pain, paraesthesiae, numbness and signs of loss of vibration and 
position sense, absent ankle reflexes and impaired cutaneous sensation. 
Most patients experience problems for months or years and in some cases 
progress to loss of pain appreciation, which in conjunction with local joint 
subluxation can result in neuropathic ulceration of the feet. In a few cases 
widespread joint disruption of the foot results in neuropathic arthropathy 
(Charcot's arthropathy). Autonomic neuropathy is less common and may 
present with diarrhoea, gastroparesis, postural hypotension, erectile 
impotence and cardiac denervation. The latter may result in fatal 
cardiorespiratory arrest.
2.2.2 Macrovascular
Morbidity and mortality due to abnormalites of the coronary, cerebral and 
peripheral arteries are increased in diabetic patients (89,90,91). Atheroma 
is generally more extensive in diabetics compared to non-diabetics (65) 
which may account for some of the increased risk. Disease of the 
microcirculation may also contribute to vascular occlusive disease (92,93) 
as may hypertension (89).
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2.3 Abnormal rheology in diabetes mellitus
2.3.1 Plasma and serum viscosity
Serum viscosity (i.e. plasma viscosity less the effect of fibrinogen) was first 
measured in diabetic patients by Cogan et al, using a capillary viscometer, 
and was found to be elevated compared to healthy controls due to 
elevations of several serum proteins (94). Elevation of plasma viscosity in 
diabetes has also been confirmed by many investigators (95-99). In most of 
these studies diabetics had raised fibrinogen levels as well as serum 
globulin levels, particularly a 2 -macroglobulin, haptoglobin and 
caeruloplasmin (100), i.e. a disturbance in the average molecular size or 
shape of plasma proteins may be causing an increase in plasma viscosity 
(101). However in other studies no difference was detected between 
diabetic and control subjects (102-104).
2.3.2 Whole blood viscosity
Because the concentration and mechanical properties of the red cells also 
contribute to whole blood viscosity, several viscometers have been 
developed to measure whole blood viscosity at different shear rates to 
reflect the range found in the vascular system. Skovborg first studied whole 
blood viscosity in diabetic patients, and throughout a variety of shear rates, 
he found that viscosity was about 20% higher in diabetic patients compared 
to controls (105). Increased whole blood viscosity has since been 
documented at both high and low shear rates in diabetes, in some cases 
related to a higher haematocrit (106) and in others the increase was 
maintained after correction to a standard haematocrit (96,97). In some
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studies, a higher viscosity was related to increased fibrinogen levels 
(99,107,108). The difference in blood viscosity between diabetic and non­
diabetic subjects is more marked at low shear rates (104,108-111) 
implying that increased red cell aggregation is an important determinant of 
viscosity increase in diabetes. There have been a few studies showing no 
difference in whole blood viscosity at any shear rate between diabetic and 
control subjects (98), however this may have been due to the use of older, 
less sensitive viscometers.
The measurement of plasma and whole blood viscosity in diabetes has 
therefore given some conflicting results. Several factors may account for 
this, eg difference in apparatus (some older viscometers being less 
sensitive), patient selection, and confounding factors affecting blood 
viscosity which is for example increased in males compared to females, 
and in smokers compared to non-smokers (112).
2.2.3 Red cell deformability
Impaired red cell deformability in diabetic patients compared to non­
diabetic control subjects has been found by several workers using filtration 
techniques (96,98,104,113-116) and also by others using micropipettes 
(117) However several other studies have found no difference in red cell 
deformability between diabetics and non-diabetics (103,109,118). It has 
been suggested that decreased whole blood filtration may reflect 
leucocytosis in diabetics (103,119). Increased microviscosity of the 
membrane has been reported in diabetes using techniques such as 
fluorescent probes (120,121). It has been suggested that increased 
glycosylation of the membrane may cause stiffening but although this has 
been demonstrated in old cells (122,123) there appears to be no difference
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in deformability between old diabetic and old non-diabetic cells (124).
The cell membrane contains a fluid phophorylated protein, spectrin, in 
which the enzymes Na+/K+ ATPase and C a 2+/M g 2+ ATPase are located. 
Increased spectrin glycosylation has been reported in diabetic red cells, but 
this was not associated with membrane stiffening (125). It may alternatively 
be reduced spectrin phosphorylation that is responsible for the increased 
membrane viscosity in diabetic patients (126).
Reduced ATP levels have also been associated with impaired red cell 
deformability: this may be due to either calcium accumulation within the red 
cell or spectrin cross-linkage (127).
O ther work has suggested that an im balance of the 
cholesterol/phospholipid ratio in the membrane may increase its 
microviscosity (128,129).
Further evidence for a red cell membrane defect in diabetes comes from the 
study of Wautier et al, who found increased adhesion of diabetic 
erythrocytes to endothelial cells, an abnormality also present in sickle cells 
(130).
2.3.4 White cell deformability
Leucocytosis has been reported in diabetic patients (131) and Stuart et al 
have reported reduced whole blood filterability in diabetic patients to be 
related to a raised white cell count (103). Newer filtration instruments such 
as the Carri-Med filtrometer allow the initial red cell filtration rate to be 
measured independently of the residual white cell count (52). Because this 
apparatus can also measure the clogging rate of the filter, it is also possible 
to determine white cell deformability. Reduced white cell filterability has 
been found in diabetic patients using this system (116,132)
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2.3.5 Red cell aggregation
By direct observation, Ditzel first described increased red cell aggregation 
in the microcirculation of diabetic patients (133) but since then there have 
been few studies measuring red cell aggregation directly in diabetic 
patients. One study found no increase in aggregation in microchambers 
implanted in skin flaps of diabetic patients, though the numbers involved 
were small and the contribution of the endothelium was excluded (134). 
Schmid-Schonbein found an increased resistance to dispersion of 
aggregates at high shear rates in vitro in diabetic patients, which was 
associated with their abnormal plasma proteins (96). Other workers have 
confirmed increased aggregation in diabetic compared to non-diabetic 
subjects (135,136).
Diabetes therefore appears to be associated with increased red cell 
aggregation compared to non-diabetics. This is associated with increased 
plasma proteins, particularly fibrinogen, but may also be associated with 
reduced red cell size (28).
2.4 Glycaemic control and rheology
Very high levels of blood viscosity are found in diabetic ketoacidosis (137) 
due both to dehydration (causing haemoconcentration) and increase in 
acute phase proteins. It might therefore be expected that viscosity is related 
to glycaemic control. This, however, has only been found in a few studies 
(95,100) although changes in viscosity have been observed with 
improvement in glycaemic control (106,138).
Impaired red cell deformability in diabetes has been related to poor
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glycaemic control (96,98,106,120), but incubating red cells, both diabetic 
and non-diabetic, with glucose to increased intracellular sorbitol levels 
produced only a minor reduction in deformability (115). Other studies have 
found no relationship with glycated haemoglobin (HbA1) or blood glucose 
levels (113,116,117,119). Juhan et al found that deformability of normal 
red cells was reduced after incubation in plasma from uncontrolled diabetic 
patients, despite a lack of correlation of deformability with glycaemic control 
(139). They subsequently showed that reduced membrane fluidity in 
diabetic cells could be corrected by insulin in vitro (140). Filterability of red 
cells was improved in one longitudinal study after insulin infusion for three 
months (141).
Many large serum proteins as well as fibrinogen may be elevated in 
diabetic patients, often as part of an acute phase reaction to infection or 
during periods of poor glycaemic control (131). Bauersachs et al found 
increased red cell aggregation associated with increased fibrinogen in 
uncontrolled type 2 diabetic patients, which was not improved by short term 
insulin treatment (142).
2.5 Rheology and microvascular complications in diabetes
2.5.1 Blood viscosity
Non-diabetic conditions such as myeloma and Waldenstrom's 
macroglobulinaemia which are associated with increased blood viscosity, 
are also associated with retinopathy. It is possible therefore that the 
increased viscosity of diabetes could contribute to the progression of 
diabetic retinopathy. Dintenfass measured viscosity in a group of diabetic
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patients with retinopathy and compared them with a group of patients with 
non-diabetic retinopathy, but found the viscosity to be highest in the non­
diabetic male patients (143). Lowe et al found no difference in viscosity in a 
group of male diabetics with background diabetic retinopathy compared 
with a similar group having no retinopathy (97), but in a subsequent study 
blood viscosity was increased, especially at low shear rates in patients with 
proliferative retinopathy compared with those having minimal change or no 
retinopathy (99). Other investigators have confirmed an increase in low 
shear rate viscosity in patients with retinopathy although the grade of 
retinopathy was not always stated (107,109,111). In a prospective study, 
Barnes et al have found that abnormal blood rheology was predictive of 
deterioration in retinopathy over a three year follow-up period (144).
There has been little work on blood viscosity in diabetic nephropathy. 
Nevertheless, Simpson has suggested that increased viscosity in diabetes 
may cause an increased perfusion pressure in the glomerulus, thus leading 
to proteinuria (145). Hill et al, however showed that in diabetic children 
viscosity was not related to microalbuminuria (108) . Similarly it has been 
suggested that altered blood rheology could contribute to decreased flow in 
nerve capillaries (146) but there is little evidence to support this hypothesis.
2.5.2 Red cell deformability
Abnormal red cell deformability could in theory have a detrimental effect on 
diabetic retinopathy by reducing blood flow and contributing to hypoxia in 
the microcirculation. There have been conflicting reports of red cell 
deformability in association with microvascular complications , several 
studies have found reduced deformability (103,109,113,114) and others no 
difference (96,108). Sewchand found no difference in red cell membrane
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properties between healthy non-diabetics and diabetic patients with 
retinopathy (147). Lowe et al found no statistically significant difference in 
red cell filterability between diabetics with proliferative retinopathy and 
those with background or no retinopathy (99), although a trend to impaired 
filterability in the former group was apparent
2.5.3 White cell deformability
Leucocytosis and decreased white cell deformability in diabetic patients 
could contribute to impaired blood flow in the microcirculation, possibly 
promoting the increased microvascular complications seen in diabetes. 
Using the Carri-Med filtrometer and white cell suspensions, Vermes et al. 
found increased clogging of filters, presumably due to reduced white cell 
deformability, in diabetic patients with retinopathy compared to those with 
no retinopathy (132).
There have been few studies of white cell filtration in diabetic patients as a 
whole compared with non-diabetics.
2.5.4 Red cell aggregation
An increase in red cell aggregation would increase blood viscosity at low 
shear rates, which may promote blood stasis. This could induce local 
hypoxaemia and endothelial damage and in diabetic patients this could be 
yet another mechanism contributing to microvascular complications.
In Ditzel's study he found increased red cell aggregation in the 
microcirculation of diabetic patients known to have microvascular 
complications, though there was no difference between patients who had 
proliferative retinopathy alone and those who also had nephropathy (133) 
Increased red cell aggregation has been reported in diabetic patients with
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retinopathy (136) but other studies have found no difference in aggregation 
between patients with retinopathy and those without, although the degree 
of retinopathy was not always specified (96,135)
As in studies of viscosity and red cell deformability in diabetic nephropathy, 
there is little published work on red cell aggregation in this subgroup of 
patients. Non-diabetic patients with nephrotic syndrome appear to have 
increased red cell aggregation which was not related to renal function, but 
which was related to increased fibrinogen levels (148). It is therefore likely 
that diabetic patients who have increased fibrinogen levels (101) will have 
a further increase in aggregation if they develop nephropathy.
2.6 Rheology and macrovascular complications in diabetes
In large vessel disease the narrowing of the lumen due to atherosclerosis 
will eventually impede flow, and since blood viscosity is inversely related to 
blood flow a rise in whole blood viscosity would therefore further reduce the 
blood supply to vital organs. In the capillaries, impaired red and white cell 
deformability may cause further ischaemia as may increased red cell 
aggregation in venules. Diabetic patients with abnormal rheology have 
therefore an additional risk factor for vascular complications. The increased 
plasma viscosity and impaired cellular deformability may be partly a 
secondary phenomenon due to acute and/or chronic phase responses 
induced by damage to vessels or tissues. Such responses are 
characterised by increased fibrinogen and serum protein levels and a 
leucocytosis, which will increase plasma and whole blood viscosity and 
reduce blood filterability thus exacerbating the degree of ischaemia.
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2 .6.1 Cerebrovascular disease
Increased haernatocrit and blood viscosity have been associated with 
reduced cerebral blood flow, while venesection causes a fall in viscosity 
and increase in cerebral blood flow (149). Reduced red cell deformability 
has been described in stroke patients and may be an cause of ischaemic 
damage (150). In diabetic patients reduced vasodilatory reserve in the 
cerebral circulation (151) coupled with raised viscosity may partly expain 
why patients with diabetes mellitus have an increased risk of stroke. 
Rheological studies of diabetic patients with cerebrovascular disease are 
awaited.
2.6.2 Ischaemic heart disease
Studies of patients with ischaemic heart disease have found increased 
blood viscosity associated with a raised haernatocrit (152) and raised 
fibrinogen levels (153), whereas others have shown no difference in the 
individual determinants of viscosity between patients with stable angina 
and those with no heart disease (154,155). In patients who have suffered a 
myocardial infarction, reduced blood filterability was found within the first 12 
hours after infarction, along with increased plasma and whole blood 
viscosity (156). In patients with abnormal rheology this may contribute to 
extension of infarct size. Conversely, reduction of infarct size by 
thrombolytic therapy may reflect reductions in plasma fibrinogen, plasma 
viscosity and blood viscosity as well as lysis of coronary thrombi.
Diabetic patients with abnormal rheology again would be more susceptible 
to ischaemic damage with resultant poor ventricular function, and this may 
be relevant to the increased incidence of cardiac failure found in these
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patients (157). There have been few studies looking at viscosity and 
deformability in diabetic patients with ischaemic heart disease. Activation 
of white cells causes a reduction in their deformability (158) and recently 
reduction in filterability of white cells due to activation has been 
demonstrated in post-myocardial infarct patients (159)
Hypertension is a major cause of both cerebrovascular and cardiovascular 
disease and the incidence of hypertension is increased in diabetic patients 
(89,160). Hypertension has also been associated with raised viscosity in 
non-diabetic patients (161) and could be one mechanism leading to 
increased vascular complications in these patients. Hypertension may 
reflect increased cardiac output against a raised viscosity which has 
increased the peripheral resistance.
2.6.3 Peripheral vascular disease
Peripheral vascular disease is a major problem in the elderly, especially 
smokers and diabetic patients. In the latter the problem is compounded by 
microvascular disease and by peripheral neuropathy. Any increase in 
viscosity, reduction in red or white cell deformability or increase in red cell 
aggregation could reduce the blood supply to tissues which are already 
ischaemic. Reduced filterability of whole blood has been shown in patients 
with peripheral vascular disease in association with a raised white cell 
count which is probably due to a chronic phase response (162). In diabetic 
patients better healing of amputations is found in the patients with the 
lowest pre-operative haemoglobin levels, suggesting a deleterious effect of 
haernatocrit on blood flow (163). Whether therapeutic reduction of 
haernatocrit increases healing of amputations in diabetics is not 
established.
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2.7 Summary
Both plasma and whole blood viscosity are elevated in diabetic patients 
due mainly to increased plasma proteins causing increased plasma 
viscosity and increased red cell aggregation at low shear rates. 
Abnormalities of red and white cell deformability are more controversial and 
depend on the methodology used (164), but it does seem that there are cell 
membrane abnormalities associated with the diabetic state which could 
well increase cell rigidity.
The contribution of rheological abnormalities to specific diabetic 
complications requires to be established.
2.8 Scope of the present thesis
1. Using established techniques for measuring whole blood viscosity, it was 
aimed to assess whether or not abnormal viscosity in diabetes was related 
to complications not previously studied, i.e. hypertension and diabetic 
neuropathy.
2. It was aimed to evaluate the new Carri-Med filtrometer for the 
measurement of red cell deformability, and the Myrenne erythrocyte 
aggregometer for red cell aggregation, in diabetic patients compared with 
non-diabetic control subjects and to determine if any abnormalities 
detected were related to vascular complications.
3. With a recently developed method for separating white blood cell 
subpopulations and a modified filtration technique, it was aimed to measure 
white cell deformability in diabetic patients compared with non-diabetic 
control subjects.
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CHAPTER 3 
METHODOLOGY
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3.1 Preparation of blood samples
The experimental work in this thesis as far as possible followed the 
guidelines of the International Committee for Standardisation in 
Haematology (ICSH) for blood sampling and handling (165,166).
Venous blood was used in all studies, this was collected in the morning 
after minimal venostasis from rested subjects using a large bore (to avoid 
high shear damage to cells), sterile needle. For all rheological procedures, 
routine haematology and glycated haemoglobin samples, 5 ml aliquots of 
blood were anticoagulated with dry potassium edetate (EDTA, 1.5mg/ml). 
This particular anticoagulant was used to minimise platelet aggregation, 
and because it has least effect on red cell morphology and plasma viscosity 
and avoids dilution of samples which is an additional variable with liquid 
anticoagulants (3). EDTA is recommended for anticoagulation in 
measurements of blood viscosity, red cell deformability and red cell 
aggregation (167,168)
Samples were analysed within 2 hours of venesection, and 2ml of plasma 
supernatant was used on the same day for analysis of plasma viscosity 
(3.3). An aliquot of citrated plasma was stored at -20°C for later analysis of 
plasma fibrinogen, and aliquots of serum were stored for serum protein 
measurements (3.9).
3.2 Haernatocrit
Blood was drawn from the EDTA tube into duplicate 1mm diameter glass 
capillaries, and after the end was heat-sealed, they were centrifuged at 
13000 xg for 5 minutes in a Hawksley Microcentrifuge (Gallenkamp, 
Glasgow). Microhaematocrit was read as the percentage red cell pack to
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that of the whole sample, the reading used being the mean of two samples.
3.3 Plasma viscosity
Plasma viscosities were measured in the Coulter-Harkness semi-automatic 
capillary viscometer (Coulter Electronics Ltd., Harpenden, Hertfordshire). 
This instrument was chosen for ease of handling, accuracy, speed of 
measurement and small sample volume requirement (45).
After calibration using distilled water as the standard fluid, 0.5ml of plasma 
was pipetted into the sample cup at one end of the horizontal capillary. It is 
drawn through the capillary (0.38 mm in diameter) using a constant head of 
pressure applied by a mercury column. The time taken for the sample to 
travel is recorded by the mercury meniscus moving in a capillary parallel to 
the sample activating an electronic timer. The reading on the timer is made 
equivalent to the value of the sample's viscosity and is displayed on a 
register in mPa.s. The capillary system is immersed in a thermostatically 
controlled water bath at 37°C.
The mean of duplicate readings was taken. The coefficient of variation 
within samples was less than 1%.
3.4 Whole blood viscosity
3.4.1 Contraves LS 30 rotational viscometer
Low and high shear viscometry was performed in the Contraves LS 30 
rotational viscometer (Contraves Industrial Products Ltd., Ruislip, 
Middlesex), which is a coaxial cylinder (couette) viscometer (48).
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Measurements were made with the 2T bob and cup system on 2.5ml of 
whole blood. The shear rate is a function of the cup's geometry and 
rotational speed. Rotating the cup produces a torque by the sample on the 
bob. The bob is attached to a torsion wire which is linked to a mirror and 
tilting system and the torque transmitted from the sample on the bob is 
sensed in the reflected light source and monitored by a photo-electrical 
system. An equal and opposite torque is produced from a regulating 
current passing from a differential amplifier through electromagnetic coils
concentric with a ferrite core attached to the torsion wire. The strength of
the current is proportional to the torque from the sample and the sample's 
viscosity can be calculated from the following equation:
Viscosity = shear stress = torque x K
shear rate rotational speed
(K = conversion factor determined by the system geometry and evaluated 
using standard Newtonian silicone oils).
A Rheoscan 20 programming unit was used allowing measurements over 
an accelerating shear rate ramp. This was used for the studies of diabetic 
patients with hypertension (chapter 4), while a constant shear rate 
measurement was used for the studies of diabetic patients with peripheral 
neuropathy (chapter 6).
3.4.2 Experimental procedure
The machine was calibrated with standard silicone oils (viscosities 7.6, 
13.6, and 20.3mPa.s at 37°C). The sample was manually mixed using the 
bob for 5 seconds and the measurement procedure started. The constant
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shear measurements were performed during the next 15 seconds with the 
sample at 37°C. Low shear viscosity was measured at 0.945 s-1 and high 
shear at 94.5 s-1. High shear viscosity measurements were made first, 
since high shear mixing of the sample for 10 seconds is the most 
convenient way of breaking up red cell aggregates (169). The accelerating 
shear programme also measured high shear rate (94.5s-1) viscosity first, 
then low shear rate (0.945s-i) viscosity. Viscometry results were recorded 
as chart traces of torque reading as a function of time using a Bryans 27000 
chart recorder and taking the peak value for constant shear measurements 
as recommended by the ICSH (166). Blood viscosity was measured at 
native haernatocrit and a mathematical method of correction to a standard 
haernatocrit of 45% (0.45) was used (7):
0.45 
native Hct
Blood viscosity (Hct 0.45) _ r Blood viscosity (native Hct) *
Plasma viscosity L Plasma viscosity J
This equation is based on the linear relationship between the logarithm of 
relative blood viscosity and haernatocrit (170). The coefficient of variation at 
a shear rate of 94.5s-1 was 2.5% and at 0.945s-1 was 2.2%. The 
contributions of red cell factors (deformation and aggregation) and plasma 
viscosity at the standard haernatocrit were assessed by calculating the ratio 
of blood viscosity to the measured plasma viscosity, i.e. relative viscosity.
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3.5 Red cell Deformability
3.5.1 Carri-Med filtrometer
Red cell deformability was measured using the St. George’s filtrometer 
(Carri-Med Ltd., Dorking, UK), (Figure 3.1). This system utilises a vertically 
positioned filter, to minimise red cell sedimentation causing filter blocking. 
The red cells are drawn through the filter by a constant but adjustable 
negative pressure of water. The rate of filtration is measured by the times 
taken for the sample meniscus to flow past 4 light detectors and this 
information is stored on an interfacing BBC computer. Three subsequent 
steps of 20 pi sample volume flow are used, and the initial filtration rate is 
determined by extrapolating back to time zero. The clogging rate of the 
filter can also be determined. The initial filtration rate of red cells is 
independent of white cell clogging (52).
3.5.2 Preparation of samples
5 mis of EDTA-anticoagulated venous blood was centrifuged at 1500 xg for 
10 minutes in a Mistral 4L centrifuge at ambient temperature. The plasma, 
buffy coat and upper 10% of red cells were discarded. Two ml from the 
middle of the red cell column were suspended in pre-filtered phosphate 
buffer saline (pH 7.4, 290 mOsm/kg) at a haernatocrit of 10%. (Sensitivity to 
individual cell properties is optimal at haematocrits less than 15%).
3.5.3 Filtration procedure
Phosphate-buffer saline was filtered through a Nuclepore polycarbonate 
filter (pore diameter 5pm, Nuclepore Corporation, Pleasanton, CA, USA;
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Figure 3.1 Carri-Med filtrom eter
constant batch number 54B4D10) and the initial filtration rate recorded on 
the computer. The red cell suspension was then introduced to the capillary 
and the filtration rate measured through the same filter. A 3 cm negative 
filtration pressure was used throughout and studies were performed at 
25°C. The initial filtration rate of the suspension was expressed in relation 
to the buffer filtration rate as a ratio (red cell filtration ratio). Within sample 
coefficient of variation was 4.5%
3.6 Red cell aggregation
3.6.1 Myrenne aggregometer
Red cell aggregation was assessed photometrically using the highly 
automated Myrenne cone-plate aggregometer (Myrenne GmbH, Roetgen, 
FRG). Measurement is based on the light transmitting properties of 
aggregating suspensions. The amount of light transmitted is dependent on 
the shear rate applied. At high shear rates increased light transmission 
occurs due to the deformation of cells with flow streamlines, and at low 
shear rates the increased light transmission with time is due to the cell-free 
gaps associated with rouleaux formation. (Figure 3.2)
The Myrenne aggregometer was developed from the work of Schmid- 
Schonbein et al (58) and consists of a transparent perspex cone and plastic 
plate, the latter being fixed in position and shearing of the sample achieved 
by rotation of the cone. Infrared light transmitted through the sample is 
measured by a photometer which produces photovoltages (mV) that are 
processed in a microprocessor unit incorporated within the machine.
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3.6.2 Experimental procedure
The intensity of the light source transmitted through the cleaned cone and 
plate of the Myrenne aggregometer was logged with the chamber closed 
and stored by pressing 'A' (adjust) key. At 25°C, 20 pi from an EDTA- 
anticoagulated blood sample was then pipetted onto the centre of the cone 
and the plate lowered into position by closing the cover. The sample was 
sheared at 600/s for 10 seconds to give a baseline reading and the 
increase in light transmission was then measured over a 5 second period of 
stasis (M mode) and integrated via the microprocessor unit and displayed 
digitally as the aggregation index. Aggregation was measured twice for 
each sample and the average of the duplicate readings taken as the mean 
aggregation index. The measuring system was cleaned between each new 
sample. Measurements were made first at native haernatocrit, and after 
samples had been reconstituted to a standard haernatocrit of 40% 
aggregation was measured twice again. The coefficient of variation was 
5.2%. Aggregation was measured at standard haernatocrit as well because 
aggregation is haernatocrit dependent, increasing between haematocrits of 
20-45% and decreasing at haematocrits above 40-45%.
3.7 White cell deformability
The methods used were those of Lennie et al (31).
3.7.1 Preparation of buffer
Phosphate buffer saline (PBS) was prepared from 42.5 g sodium chloride, 
1 g potassium chloride, 1 g potassium dihydrogen orthophosphate and
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5.75 g disodium hydrogen orthophosphate in distilled water at 4°C. pH 
was adjusted to 7.4 and osmolality to 290 mOsm/kg.
Before use the PBS was mixed with 0.5% w/v bovine serum albumin (BSA, 
Sigma, UK) and the solution filtered through a 0.45|im bacterial filter 
(Millipore, UK).
3.7.2 Separation of white cells
4 ml of mono-poly resolving medium was prepared from 15.454g sodium 
metrizoate and 8.182g Ficoll 400 mixed to 100mls with distilled water, 
giving a solution with a specific gravity 1.114 g/ml and an osmolality of 300 
mOsm/kg.
1 ml of lymphoprep, a solution with a specific gravity of 1.114 g/ml and 
osmolality of 300 mOsm/kg, (Nyegaard, UK) was layered on top of the 
mono-poly resolving medium. Although mono-poly resolving medium 
separates mononuclear and polymorphonuclear cells in a one step 
procedure the resolution of cells was improved by modifying the separation 
technique with the addition of lymphoprep.
These solutions were placed at the bottom of a plastic tube and 5 ml of 
anticoagulated blood was layered on top of both. The mixture was 
centrifuged at 200 xg in a Mistral 4L centifuge for 40 minutes at ambient 
temperature.
After centrifugation the leucocyte subpopulations appear as two separate 
bands, the upper layer being the mononuclear cells (monocytes and 
lymphocytes) and the lower the polymorphonuclear cells (Figure 3.3) Each 
fraction was aspirated and added to 10 ml PBS/BSA and centrifuged at 200 
xg for a further 10 minutes.
The supernatant was discarded and the cells resuspended in a known 
volume of PBS/BSA to a concentration of 105/l.
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Figure 3.3
Separation technique for white blood cell subpopulations
3.7.3 Filtration procedure
The apparatus consisted of a syringe pump (Treonic,Vickers, UK) with a 60 
ml plastic syringe connected via a rigid 3-way plastic connector to a "pop- 
top" filter holder which holds a Nuclepore polycarbonate membrane, pore 
diameter 5 pm, batch number 54B4D10 (Sterilin, UK). The filter holder is 
connected to a pressure transducer (Bell and Howell, UK) which in turn is 
linked to a pressure indicator/amplifier (Gaeltech, UK). The transducer was 
calibrated using a pressure manometer to give a range of 0-20 cm water on 
the chart recorder. Pressure changes were monitored on a Servoscribe RE 
11 potentiometric chart recorder and were recorded as continuous 
pressure-time curves (Figure 3.4).
Filtration of the PBS/BSA used to suspend the white cells 
(polymorphonuclear or mononuclear) through the Nuclepore filter was used 
to produce a constant pressure reading. Subsequent filtration of the cell 
suspension in buffer through the same filter at a constant flow of 1.5 ml/min 
at 25°C gave a time-dependent increase in pressure due to progressive 
occupation of pores by slowly passing white cells. Pressures were 
analysed at 1 minute intervals for 6 minutes. The ratio of the pressure 
produced by the cell suspension to the pressure produced by buffer was 
calculated.
3.8 Plasma proteins
3.8.1 Serum Globulins
Total protein, albumin, and globulins (total protein minus albumin) were 
determined by SMAC on the Technicon Autoanalyser (Basingstoke), total
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Figure 3.4 White cell filtra tion  apparatus
protein was measured by the biuret method and albumin by the 
bromocresyl green method, in the hospital biochemistry department.
3.8.2 Fibrinogen
Fibrinogen was measured in a citrated plasma from a 5 ml citrated blood 
sample (4.5 ml blood = 0.5 ml 3.8% tritodium citrate) at 37° C in a Coag-a- 
mate X2 analyser (General Diagnostics, Morris Plains, NJ, USA) by the 
clotting time method of Clauss with a photo-optical system, during the 
viscosity and red cell deformability studies (chapters 4-6). Organon- 
Teknika reagents and standards were used.
The heat precipitation method (171) was used for estimation of plasma 
fibrinogen during the aggregation studies (chapter 7). Blood is drawn into 
microhaematocrit tubes, spun in the Hawksley centrifuge for 5 minutes, 
immersed in a waterbath at 57° C for 4 minutes and then centrifuged for a 
further 3 minutes in the Hawksley centrifuge. Using a X70 magnification on 
a microscope with a moving stage, the length of the fibrinogen precipitate 
was expressed as a ratio to the original plasma column (ml/100ml).
The mean of duplicate readings was taken.
3.8.3 Aipha2-macroglobulin and Haptoglobin
These large plasma proteins were measured by an immunoturbidimetric 
assay on the Encore centrifugal analyser (Baker Instruments, 
Pennysylvania). Normal ranges were determined from the healthy 
population used in the study as described in chapter 7.
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3.9 Blood cell indices
Haemoglobin concentration, mean red cell volume (MCV normal range 76- 
96 fl) and leucocyte count (WCC, normal range 4.0-11.0 x 109/l) were 
measured by Coulter -S -Counter. Mean cell haemoglobin concentration 
(MCHC) was estimated from haemoglobin concentration divided by the 
microhaematocrit measurement from the Hawksley centrifuge (g/dl).
3.10 Glycated haemoglobin and Blood glucose
Glycated haemoglobin (HbA-j) was measured by agar gel electrophoresis 
(Corning Glytrac, Palo Alto, California), laboratory normal range 5.5-8.5%.
Blood glucose was measured by the hexokinase method (Hitachi 773 
automatic analyser, Boehringer Mannheim, FRG). Normal laboratory 
fasting range 4.0-5.5 mmol/l
3.11 Plasma lipoproteins
Triglyceride, and total cholesterol, and very low density lipoprotein (VLDL), 
low density lipoprotein (LDL) and high density lipoprotein (HDL) were 
measured after overnight density separation ultra-centrifugation of plasma 
at 35000xg (Beckman, Palo Alto, California) on a Hitachi 704 automatic 
analyser (Boehringer Mannheim, FRG).
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CHAPTER 4 
ASSOCIATION OF WHOLE BLOOD VISCOSITY 
WITH HYPERTENSION IN DIABETES MELLITUS
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4.1 Introduction
Arterial blood pressure is determined by cardiac output and by total 
peripheral resistance, which is determined by both vessel geometry 
(vascular hindrance), and by blood viscosity In recent years the neglected 
contribution of raised viscosity to the pathogenesis of hypertension has 
been realised.
Blood viscosity has been found to be increased in hypertensive individuals
(161.172) and this appears to be related partly to a raised haematocrit
(161.173), which may be due to a contracted plasma volume from 
transcapillary shift of extracellular fluid from plasma caused by the 
increased arterial pressure (174). Loss of extracellular fluid will also cause 
a rise in plasma protein concentration, which would lead to both an 
increase in plasma viscosity and an increase in blood viscosity at low shear 
rates due to increased red cell aggregation. Plasma exchange, which 
reduces the level of high molecular weight plasma proteins, has been 
shown to reduce blood pressure (175). Similarly, reduction of haematocrit 
by venesection reduces blood pressure (176). One of the main plasma 
proteins contributing to blood viscosity is fibrinogen, and this has been 
shown to be independently related to the raised blood viscosity in 
hypertension (161), the increased fibrinogen perhaps being due to a 
"chronic phase response".
The other main determinant of blood viscosity at high shear rates is red cell 
deformability and this has also been shown to be reduced in hypertensive 
subjects (177.178).
Hypertension is common in diabetes mellitus (160,179), has been 
associated with both micro- and macrovascular disease (180-184), and is a
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risk factor for cardiovascular disease (66,91). Because hypertension in 
people without diabetes has been associated with increased whole blood 
and plasma viscosity, and because diabetic patients have raised blood 
viscosity (185), it is possible that there is an additive effect of diabetes and 
hypertension on viscosity, leading to the increased risk of vascular 
complications related to hypertension in diabetic patients.
The aim of this study was to assess whole blood viscosity and its 
determinants in diabetic patients with hypertension, compared to a matched 
group of diabetic patients without hypertension and a healthy control 
population, to determine if blood rheology was altered in diabetic patients 
with hypertension.
4.2 Patients
4.2.1 Diabetic patients
86 diabetic out-patients were studied (38 type 1 and 48 type 2). The mean 
age was 49 years and the range was 18-74 years. There were 41 males 
and 45 females and mean body mass index was 26.1 ± 3.9 kg/m2. The 
other clinical characteristics of the diabetic patients and control subjects are 
shown in Table 4.1.
Hypertension was defined as blood pressure > 160/95 mmHg on a 
conventional mercury sphygmomanometer on two occasions after sitting for 
10 minutes, or accepted as diagnosed in patients receiving anti­
hypertensive treatment. Because only 4 type 1 diabetic patients were 
hypertensive, these were excluded from further analysis and 34 
normotensive type 1 diabetics were compared with 23 normotensive and
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Table 4.1
Clinical characteristics and rheology of diabetic patients 
and normal subjects studied
Control
subjects
Diabetic
Patients
n 52 86
Sex (M/F) 32/20 41/45
Smokers 24 37
Age (yr) 46.0 ±5.0 49.0 ±14.0
Body Mass Index (kg /m 2 ) 26.4±4.0 26.1 ±3.9
H b A i(%) - 10.5±2.3
Haematocrit (%) 44.8 ±3.3 43.2 ±4.5
Fibrinogen (gl / I ) 3.2 ±0.7 3.0 ±0.8
Plasma viscosity (mPa.s) 1.32 ±0.14 1.45 ±0.15 a
Whole blood viscosity (mPa.s) 
95 s '1 5.0 ±0.6 5.1 +0.7
Corrected c 4.9 ±0.6 5.3 ±0.5®
0.95 s ’1 17.5±3.6 19.4 ± 4.8b
Corrected c 17.4±2.6 20.7 +2.7 a
Relative blood viscosity (mPa.s) 
9 5 s '1 3.8±0.4 3.8±0.3 ,
0.95 s-1 13.5 ±1.9 14.8 ±1.8
a p < 0.05, diabetic patients vs control subjects 
b p <  0.01, diabetic patients vs control subjects 
c Corrected to a standard haematocrit of 45%
25 hypertensive type 2 diabetic patients. 18 patients were on anti­
hypertensive medication which included a combination of diuretics, beta- 
blocking and calcium channel blocking drugs. All patients had normal urea 
and electrolyte concentrations and except for anti-hypertensive and 
diabetic medication were receiving no other drug therapy. 13 type 2 
normotensive diabetics were on insulin therapy and 10 were taking oral 
hypoglycaemic agents. In the hypertensive group, 4 were receiving insulin 
therapy while 11 were taking oral hypoglycaemic drugs and 10 were on 
dietary therapy only, Table 4.2.
Duration of diabetes was significantly longer in the type 1 diabetics (18 ± 11 
years) compared with type 2 diabetics (10 ± 6 years-normotensive and 6 ± 
5 years -hypertensive, p<0.02). The groups were well matched for 
glycaemic control (HbA1; 11.1 ± 2.1%-type 1, 10.6 ± 2.6%-type 2 
normotensive, 10.6 ± 2.3%-hypertensive, p>0.05) and the type 2 diabetics 
were well matched for sex distribution (10 male/13 female-normotensive 
and 12 male/13 female-hypertensive), age (58 ± 7 years-normotensive and 
58 ± 7 years-hypertensive) and body mass index (26.4 ± 3.9 kg/m2- 
normotensive and 27.2 ± 3.9 kg/m2-hypertensive), (Table 4.3). The 
vascular complications of all the diabetic patients are shown in Table 4.2.
4.2.2 Control Subjects
52 healthy normotensive control subjects were selected from factory 
employees. They had a mean age of 46 years and range 36-57 years. 
There were 32 males and 20 females and they were well matched with the 
diabetic patients for body mass index (26.4 ± 4.0 vs 26.1 ± 3.9 kg/m2, 
p>0.05), Table 4.1. None were taking any medication and all had normal
fasting blood glucose levels.
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Table 4.2
Mode of treatment of diabetes, and complications present in 
diabetic patients studied
Type 1 diabetes Type 2 diabetes Type 2 diabetes 
normotensive normotensive hypertensive
n 34 b 23 a 25Duration of diabetes (yr) 18±11 10+6 6±5
Treatment of diabetes
Insulin 34 13 4
Oral hypoglyceamic agents 0 10 11
Diet only 0 0 10
Treatment of hypertension 0 0 18
Diabetic complications
Background retinopathy 12 10 6
Proliferative retinopathy 3 1 2
Nephropathy 1 2 0
Neuropathy 6 4 0
Macro vascular disease 2 5 10
a p < 0.02, Type 1 vs Type 2 diabetic patients.
b p < 0.01, Type 2 normotensive vs Type 2 hypertensive diabetic patients.
Table 4.3
Clinical characteristics of diabetic and control subjects studied
Control Diabetic patients
subjects
Type 1 
normotensive
Type 2 
normotensive
Type 2 
hypertensive
n 52 
Sex (M/F) 32/20 
Smokers 24 
Age (yr) 46.0±5.0 
BMI (kg /m 2 ) 26.4±4.0 
HbA-j (%)
BP (mmHg) 128±19/80+10
34
17/17
18
37.0112.0 a 
25.21 4.0 
11.112.1 
127118/8216
23 25 
10/13 12/13 
11 6 
58.017.0 58.0+7.0 a’b 
26.4±3.9 27.2±3.9 
10.6±2.6 10.612.3 
130113/83+8 177+33 a’d /97l15a'c
a p < 0.01, diabetic patients vs control subjects. 
b p < 0.05, Type 2 vs Type 1 diabetic patients. 
c p < 0.05, hypertensive vs normotensive diabetic patients, 
d p < 0.01, hypertensive vs normotensive diabetic patients.
4.3 Methods
4.3.1 Blood samples
Whole blood viscosity (shear rates 94.5 and 0.945 s_1) and plasma 
viscosity were measured at 37°C in blood anticoagulated with EDTA within 
2 hours of venesection. Whole blood viscosity was measured in a 
Contraves LS rotational viscometer, and plasma viscosity in a Coulter- 
Harkness capillary viscometer. Microhaematocrit was measured on the 
Hawksley microcentrifuge and blood viscosity was corrected to standard 
microhaematocrit of 45%. Relative blood viscosity was calculated as whole 
blood viscosity divided by plasma viscosity.
Fibrinogen was measured from a citrated sample at 37°C on the Coag-a- 
Mate X2 analyser by the clotting time method.
4.3.2 Statistical methods
The difference in means was calculated by the Mann-Whitney U-test and 
correlation by the Spearmann rank test. Values are expressed as mean ± 
SD.
4.4 Results
Whole blood viscosity (corrected for haematocrit) at high and low shear 
rates, low shear relative viscosity and plasma viscosity were significantly 
higher in diabetic patients (5.3 ± 0.5, 20.7 ± 2.7, 14.8 ± 1.8 and 1.45 ± 0.15 
mPa.s) compared to control subjects (4.9 ±0.6,17.4 ± 2.6,13.5 ± 1.9 and 
1.32 ± 0.14 mPa.s, p<0.01). Low shear rate viscosity at native haematocrit
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was also significantly higher in diabetic parients compared with control 
subjects (19.5 ± 4.9 vs 17.6 ± 3.6 mPa.s, p<0.05), Table 4.3. There was no 
significant difference in viscosity or its determinants between type 1 or type 
2 normotensive diabetic patients (Table 4.4). Compared with the control 
group high shear corrected viscosity was 7.1% higher in the normotensive 
type 2 diabetics (5.2 ± 0.3 vs 4.9 ± 0.6 mPa.s, p<0.01) and 12.6% higher in 
the hypertensive diabetics (5.5 ± 0.4 vs 4.9 ± 0.6 mPa.s, p<0.01) and was 
significantly higher in the hypertensive than in the normotensive diabetics 
(5.5 ± 0.4 vs 5.2 ± 0.3 mPa.s, p<0.01), Table 4.5. There was no difference 
in high shear rate blood viscosity between hypertensive diabetic patients 
on treatment (5.5 ± 0.5 mPa.s) and those on no treatment (5.5 ± 0.4 mPa.s).
There was a positive correlation of fibrinogen levels with both corrected 
high and low shear rate viscosity measurements (high shear, r=0.37; low 
shear, r=0.49, p<0.001) and of blood pressure with corrected low shear rate 
viscosity (systolic, r=0.25; diastolic r=0.35, p<0.05). Although no correlation 
of viscosity was found with HbA1 (high shear, r=0.05; low shear, r=0.18, 
p>0.05) there was a weak significant inverse correlation of corrected whole 
blood viscosity with duration of diabetes (high shear, r= -0.35, p<0.01; low 
shear, r=-0.24, p<0.05), (Table 4.5).
Corrected whole blood viscosity at both high and low shear rates was 
significantly higher in type 1 diabetic patients with retinopathy (background 
or proliferative retinopathy), (5.4 ± 0.2 mPa.s-high shear, 21.2 ± 1.9 mPa.s- 
low shear) than in those without (5.0 ± 0.5 mPa.s-high shear, 18.8 ± 3.2 
mPa.s-low shear, p<0.02), but no difference was observed in type 2 
patients (5.4 ± 0.4 vs 5.3 ± 0.4 mPa.s-high shear, 21.8 ± 2.3 vs 21.1 ± 2.1 
mPa.s-low shear, p>0.05), (Table 4.6).
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Table 4.5
Correlation of whole blood viscosity with variables in 
diabetic patients
★
High shear 
WBV
(r)
*
Low shear 
WBV
(r)
Age (yr) -0.12 -0.01
Blood mass index (kg/m 2 ) 0.26 -0.09
Duration of diabetes (yr) -0.35b -0.24°
Blood pressure - systolic (mmHg) -0.07 0.25°
Blood pressure - diastolic (mmHg) -0.07 0.35 b
HbA-| (%) 0.05 0.18
Haematocrit (%) 0.12 0.01
Fibrinogen (g/l) 0.37a 0.49 a
* Corrected to haematocrit 45%
a p <0.001
b p <0.01 
c p<0.05
Table 4.6
Blood and plasma viscosity in diabetic patients with and without 
microvascular disease
Type 1 Type 2
diabetic patients diabetic patients
Microvascular disease Microvascular disease
+ - +
n 15 19 29 19
Plasma viscosity (mPa.s) 1.44±0.13 1.4210.14 1.5210.23 1.4410.15
Whole blood viscosity (mPa. s)
95 S'1 5.3±0.7 4.910.6 5.310.7 4.910.7
Corrected 5.410.23 5.010.5 5.410.4 5.310.4
0.95 s ’1 20.015.3 18.213.5 21.315.1 18.514.5
Corrected 21 .2 i1 .9a 18.813.2 21.812.3 21.112.1
a p < 0.02, Type 1 diabetic patients with microvascular disease vs without. 
b Corrected to a standard haematocrit of 45%
+  present 
-  absent
Fibrinogen levels were similar in diabetic and control groups (3.4 ± 0.8 vs
3.2 ± 0.9 g/l, p>0.05). There was no significant difference in fibrinogen 
between smokers and non-smokers in either the diabetic (3.5 ± 1.0 vs 3.1 ±
0.6 g/l) or the control groups (3.3 ± 0.8 vs 3.2 ± 0.7 g/l).
4.5 Discussion
The present study has not only confirmed the general findings of previous 
studies (see chapter 1) that blood viscosity and plasma viscosity are 
elevated in diabetes, but in addition has demonstrated for the first time that 
the presence of hypertension in diabetes is associated with a further 
increase in whole blood viscosity at a standard haematocrit, which in 
hypertensive diabetic patients is over 12% higher than in non-diabetic 
control subjects. The cause of the increased viscosity is not certain, but it 
appears to be due to the combined effects of an increased plasma viscosity 
(although this study was not powerful enough to show a significant 
difference between hypertensive and normotensive diabetic patients) and a 
decrease in erythrocyte deformability which is the remaining determinant of 
high shear viscosity.
Since this study was performed Ramping et al have confirmed higher blood 
viscosity in hypertensive diabetics (186)
The raised blood viscosity in diabetic patients was associated with a normal 
fibrinogen level, and although a raised fibrinogen has been suggested to 
be one cause of the increased viscosity in diabetics, other studies have 
found normal fibrinogen levels in diabetic patients (187). The higher 
plasma viscosity in the diabetic patients compared with controls probably 
reflects an increase in plasma proteins other than fibrinogen, as reviewed
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in chapter 1.
It may be argued that the raised blood viscosity is the result of hypertension
i.e. the combined effects of raised arterial pressure being an increased 
haematocrit and increased plasma proteins from transcapillary shift of 
extracellular fluid. This rise in blood viscosity could lead to an increase in 
cardiac load and hence promote left ventricular hypertrophy (188). 
However there is some evidence that increased blood viscosity is 
implicated in the pathogenesis of hypertension. Chien has shown that mild 
hypertension and increased blood viscosity are associated with a fall in 
vascular hindrance i.e. vasodilatation, while severe hypertension is 
associated with normal vascular hindrance i.e. loss of compensatory 
vasodilatation (189). This would tend to suggest that the increase in 
vascular resistance parallels the increase in blood viscosity.
An increase in viscosity was found in type 1 diabetic patients with 
microvascular complications as in previous studies (95,99,107,101,146). 
Thus the increased viscosity at high shear rates in hypertensive diabetics 
may be one mechanism by which diabetic patients with hypertension 
develop more complications.
4.6 Summary
Whole blood viscosity measured at high shear rate and corrected to a 
standard haematocrit of 45%, was increased in type 2 hypertensive 
diabetics. Whole blood viscosity at both high and low shear rates (at 
standard haematocrit) was increased in type 1 diabetics with microvascular 
complications.
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Prospective studies of the predictive value of blood viscosity for diabetic 
complications, both microvascular and macro vascular, are required to test 
the hypothesis that hypertensive diabetics develop more complications 
than normotensive diabetics, related to greater abnormalities in blood 
rheology. It would also be of interest to evaluate blood viscosity in 
hypertensive type 1 diabetic patients.
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CHAPTER 5
ASSESSMENT OF RED CELL DEFORMABIUTY IN 
NORMALS AND DIABETICS USING AN IMPROVED 
FILTRATION METHOD
74
5.1 Introduction
Impaired red cell deformability (filterability) has been suggested in studies 
of vascular disease (150,156), sickle cell disease (19), other 
haemoglobinopathies (190) and diabetes mellitus (185). Such changes 
may reflect alterations in the red cell membrane, shape or geometry, or an 
increase in the internal viscosity of the cell (191).
Reduced red cell deformability might impede blood flow in the abnormal 
microcirculation of diabetic patients, promoting tissue hypoxia, and hence 
could contribute to the increased incidence of microvascular disease in 
diabetes.
Previous studies assessing red cell deformability in diabetic patients have 
given conflicting results, depending partly on the methodologies employed. 
Filtration techniques in which the red cells are passed through micropore 
filters with pores of diameter 3-5pm, have found impaired deformability 
associated with diabetes in some studies, but not all (185). Reduced whole 
blood filterability has been related to the increased white cell count in 
diabetic patients, and clogging of the filter by less deformable white cells 
gives non-specific results in filtration studies (103). As discussed in 
chapters 1-3, the St. George's filtrometer (Carri-Med) measures the initial 
filtration rate of red blood cells, independently of filter clogging by rigid red 
cells.
It was aimed to measure red cell deformability by an improved filtration 
method (Carri-Med filtrometer) (52), firstly in a group of healthy non-diabetic 
individuals to determine which red cell properties and which biochemical 
constituents of the blood, if any, influence red cell filtration rates.
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In then comparing groups of diabetic patients and non-diabetic healthy 
individuals, I aimed to determine if red cell deformability, as suggested by 
some previous studies, was impaired in diabetic patients. I also wished to 
evaluate the associations of red cell deformability with type and duration of 
diabetes and with glycaemic control, and aimed to determine if 
abnormalities of deformability were related to the extent of vascular disease 
present in diabetic patients.
5.2 Subjects
5.2.1 Healthy volunteers
A fasting blood sample was taken from 66 healthy factory employees (38 
male, 28 female), mean age 47 years-male, 46 years-female, range 24-57 
years. All were normotensive, matched for body mass index (26.1 ± 2.2- 
male, 26.9 ± 5.9-female), (Table 5.1), had normal fasting blood glucose, 
urea and electrolyte concentrations, and were taking no medications.
5.2.2 Diabetic patients
69 patients (28 type 1-insulin dependent, 41 type 2-non-insulin-dependent) 
were recruited from the diabetic outpatient clinic. Mean age was 38 years- 
type 1, 58 years-type2 (p<0.001), range was 18 -70 years. They were 
matched for ratio of males to females (15 M/13 F-type 1 and 22 M/19 F-type 
2), smokers to non-smokers (14/14-type 1 and 17/24-type 2), body mass 
index (25.8 ± 4.2kg/m2-type 1 and 26.6 ± 3.7kg/m2-type 2), and glycaemic 
control (HbA1; 11.3 ± 2.3%-type 1 and 10.6 ± 2.6%-type 2),
Table 5.2.
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Table 5.1
Characteristics of the non - diabetic group, filtration 
ratios, red cell indices and plasma constituents
Males 
(n = 38)
Females 
(n = 28)
Age (yr) 47 ± 5 46 ± 4
Body Mass Index (Kg/m2 ) 26.1 ± 2.2 26.9 ±5 .9
Smokers (n) 13 13
RCF ratio 0.545 ± 0.04 0.543 ±0.02
Mean cell volume (fl) 91.6 ± 5.2 93.7 ±6 .2
Mean cell haemoglobin 
concentration (g/dl)
32.4± 1.4 31.3 ± 1.0
Microhaematocrit (%) 45.8 ± 3.2a 43.1 ±3.1
White cell count (x109/l) 6.4 ± 1.7b 7.6 ± 1.7
Globulins (g/l) 25.4 ± 2.9 25.0 ±3.9
Fibrinogen (g/l) 3.2 ± 0.8 3.2 ±0.6
Osmolality (mmol/l) 288 ± 3 284 ± 4
Triglyceride (mmol/l)
g
2.0 ± 1.1 1.3 ±0.6
Cholesterol (mmol/l) 6.2 ± 1.1 5.9 ± 1.3
p < 0.011 Ma|e volunteers v Female volunteers 
p < 0.05 J
* RCF = Red Cell Filtration
Table 5.2
Characteristics of the diabetic and control groups
Control Diabetic patients
subjects type 1 type 2
n 66 28 41
Age (yr) 44±8 38± 12 58+7 a
Sex (M/F) 38/28 15 /1 3 22 /19
Smokers (Y/N) 26 /40 1 4 /1 4 17 /24
BMI (Kg/m2 ) 26.2±4.0 25.8±4.2 26.6±3.7
Duration of diabetes (yr) - 17 ± 11 8±6 3
HbA-| (%) - 11.3±2.3 10.6±2.6
a p < 0.001, type 2 v type 1 diabetics or control subjects
Patients were divided into three groups according to vascular 
complications: no complications, microvascular complications only, or both 
micro and macrovascular complications.
Microvascular disease was defined as the presence of retinopathy on 
ophthalmology (performed by myself through dilated pupils), background 
retinopathy being the presence of microaneurysms, "dot and blot" 
haemorrhages and hard exudates and/or nephropathy which was defined 
as persistant proteinuria (albustix positive) in a longstanding diabetic 
patient. Macrovascular disease was accepted as present in patients with 
documented evidence of ischaemic heart disease, cerebrovascular disease 
or peripheral vascular disease.
5.3 Methods
5.3.1 Blood samples
The blood was anticoagulated with EDTA and analysed within 2 hours of 
venesection. Red cell deformability was measured from a 5 ml sample by 
bulk red cell filtration on the Carri-Med filtrometer as described (chapter 
3.6). Samples were analysed for mean cell volume (MCV, normal range 
76-96 fl) and white cell count (WCC, normal range 4.0-7.5 x109/l) on the 
Coulter-S-Counter (3.10). Mean cell haemoglobin concentration (MCHC) 
was estimated from the haemoglobin concentration (measured on the 
Coulter-S-Counter) divided by the microhaematocrit (measured on the 
Hawksley microcentrifuge, chapter 3.2).
Serum triglyceride and cholesterol concentrations were measured by 
automated enzymatic colourimetric analysis (Hitachi 704, chapter 3.11), 
and plasma fibrinogen by the clotting time (Clauss) method (chapter 3.8.2).
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Serum osmolality and globulins were measured by SMAC (Technicon, 
Basingstoke, chapter 3.8.1).
5.3.2 Statistical methods
Parametric analysis was utilised when the control subjects were examined 
independently from the diabetic patients i.e. the Student's independent t- 
test was used to compare difference in the means, and correlation 
coefficients were by the least squares method.
Non-parametric analysis was used when diabetic and control subjects were 
compared and for analysis within the diabetic group alone, since it could 
not be assumed that the variables examined were normally distributed in 
diabetic patients. Statistical analysis was by the Mann-Whitney U-test and 
Spearman rank correlation. Values throughout are expressed as mean ± 
SD.
5.4 Results
5.4.1 Healthy volunteers
In male volunteers compared with female volunteers, triglyceride level and 
microhaematocrit were significantly higher (2.0 ± 1.1 mmol/l vs 1.3 ± 
0.6mmol/l, p<0.01 and 45.8 ± 3.2% vs 43.1 ± 3.1%, p<0.01) whereas white 
cell count was significantly lower (6.4 ± 1.7 x109/l vs 7.6 ± 1.7 x109/l, 
p<0.05, Table 5.1)
There was no difference in red cell filtration ratio between males and 
females (0.545 ± 0.04 vs 0.543 ± 0.02) nor between smokers and non- 
smokers (0.545 ±0.03 vs 0.544 ± 0.03).
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A weak significant inverse correlation of red cell filtration ratio with mean 
cell volume was found (r = -0.28, p<0.05, Figure 5.1), but no correlations 
were found with age, body mass index, serum lipids, osmolality, plasma 
fibrinogen, globulins, microhaematocrit, mean cell haemoglobin 
concentration or white cell count, (Table 5.3).
5.4.2 Diabetic patients and control subjects
The diabetic and control groups were well matched for body mass index, 
and ratio of males to females and ratio of smokers to non-smokers. Type 2 
diabetic patients were significantly older than type 1 diabetic patients and 
control subjects, although the age range of control subjects matched the 
complete range in the diabetic patients (Table 5.3).
5.4.2 (i) Effect of type of diabetes.
Red cell filtration ratio was significantly decreased in both type 1 (0.470 ± 
0.05) and type 2 (0.488 ± 0.06) diabetic patients compared to control 
subjects (0.549 ± 0.03, p<0.001) and in type 1 compared to type 2 diabetics 
(p<0.03), (Figure 5.2).
5.4.2 (ii) Relationship between red cell filtration ratio and red cell and white 
cell indices.
The difference in filtration ratio was partly related to a higher mean cell 
haemoglobin concentration in the diabetic patients, which in turn was 
related to a significantly lower mean cell volume in the diabetic patients 
compared with the control subjects, (Table 5.4). There was no difference in 
mean cell haemoglobin concentration or mean cell volume between type 1 
or type 2 diabetic patients.
Red cell filtration ratio was inversely related to mean cell haemoglobin
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Figure 5.1
Correlation of red cell filtration ratio with 
mean cell volume in normal individuals
Table 5.3
Red Cell Filtration Ratio in Normal Indivduals: 
Correlation with variables
Age (yr) 0.13
Body Mass Index (kg/m2) -0.16
Triglyceride (mmol/l) -0.17
Cholesterol (mmol/l) 0.06
Haematocrit (%) 0.02
White blood cell count (x109/I) 0.08
Mean cell volume (fl) -0.28 a
Mean cell haemoglobin concentration (g/dl) -0.01
Plasma viscosity -0.17
Fibrinogen (g/l) 0.17
Globulin (g/l) -0.08
ap< 0.05
Type I Type 2
■ Subjects 1-----------------------------Patients--------------------
Figure 5.2
Red cell filtration ratios in diabetic and control subjects
Table 5.4
Haematological and biochemical variables in diabetic 
patients and control subjects
Control Diabetic patients
subjects type 1 type 2
White cell count (x109/l) 6.9±1.8 7.4± 1.5 7.3 ± 1.7
Mean cell volume (fl) 92±6 8 9 ± 4 a 8 8 ± 5 3
Mean cell haemoglobin 31.9±1.4 33.0± 2.6 b 33.6± 1.7 b
concentrations (g/dl) 
Microhaematocrit (%) 44.7±3.4 43.4± 4.8 43.5± 4.7
Fibrinogen (g/l) 3.2±0.7 3.3± 0.9 3.4±0.7
Globulin (g/l) 25.2±3.3 25.5±3.4 26.3±3.6
1 P < 1 diabetic patients v control subjectsb p < 0.0003 J K
concentration (r- - 0.43, p<0.01, Figure 5.3) but no correlations were found 
with white cell count, haematocrit, plasma fibrinogen or globulin level 
(Table 5.5).
No association of red cell filtration ratio with glycaemic control was found as 
measured by glycated haemoglobin (r = 0.07) nor with duration of diabetes 
(r = 0.08).
To assess whether the higher mean cell haemoglobin concentration in the 
diabetic patients could account for their lower deformability, red cell fitration 
ratios in diabetics and controls with similar mean cell haemoglobin 
concentrations were compared: the filtration ratio was still significantly 
lower in the diabetic patients (0.494 ± 0.05) compared with the control 
subjects (0.553 ± 0.38, p<0.001).
5.4.2 (iii) Effect of vascular disease.
Diabetic patients with microvascular disease had significantly longer 
duration of disease than either patients with no complications or patients 
with both micro and macrovascular disease, although the ratio of type 1 and 
type 2 diabetics was similar in this group.
Red cell filtration ratio was similar in all three groups (0.487 ± 0.05-no 
complications, 0.478 ± 0.04-microvascular complications, 0.495 ± 0.04- 
microvascular + macrovascular complications) and no differences in the 
determinants of red cell deformability were found between the three groups, 
(Table 5.6)
5.6 Discussion
Deformability of the red cell was measured by a filtration method in which 
cells traverse filters with 5fim diameter pores, and from which the initial
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Correlation of red ceil filtration ratio with mean cell 
haemoglobin concentration in diabetic and control subjects
Table 5.5
Red cell filtration ratio in diabetics: 
Correlation with variables
Age (yr) 0.20
Body Mass Index (kg/m2) 0.08
Duration of diabetes (yr) 0.08
Cholesterol (mmol/I) 0.07
Haematocrit (%) -0.08
White blood cell count (x109/l) -0.04
Mean cell volume (fl) 0.02
Mean cell haemoglobin concentration (g/dl) -0.30a
Plasma viscosity
Fibrinogen (g/l) -0.22
Globulin (g/l) 0.20
ap<0.01
Table 5.6
Association of red cell filterability and other variables 
with vascular complications in diabetic patients
Microvascular &
No
complications 
(n = 32)
Microvascular 
complications 
(n = 20)
macrovascular 
complications 
(n = 17)
Red cell filterability ratio 0.487± 0.05 0.478± 0.04 0.495± 0.04
Fibrinogen (g/l) 3.1 ±0.8 3.4± 0.9 3.6± 0.6
Microhaematocrit (%) 44.3± 4.6 42.1 ± 5.2 43.2+ 4.0
White cell count (x109/l) 7.3± 1.5 7.0± 1.4 7.7± 2.0
Globulin (g/l) 26±4 26 ± 3 2 6 + 4
HbA! (%) 11.0±2 10.7± 2.3 10.9± 3.0
Duration of diabetes (yr) 8±6 18± 1 ia 10± 9
Type 1 (n) 14 10 4
Type 2 (n) 18 10 13
a p < 0.02, patients with microvascular disease v patients with
micro and macrovascular disease or no complications
filtration rate of the cells can be extrapolated from the clogging rate of the 
filter.
No difference in red cell deformability was found between males and 
females, and no effect of smoking, age or body mass index was observed in 
either the healthy volunteers or the diabetic patients. In the healthy 
subjects deformability was inversely related to mean cell volume, but there 
was no relationship to mean cell haemoglobin concentration (a measure of 
internal cell viscosity which is a determinant of deformability (191)). This 
finding may indicate that larger cells have difficulty passing through 5pm 
pores. These results are similar to those of Bareford et al (17) who 
correlated the mean cell volume with impaired red cell deformability 
through 5 pm pore diameter Nucleopore filters in the Hemorheometre (r = 
0.21, p<0.05).
A higher mean cell haemoglobin concentration in association with lower 
mean cell volume was found in diabetic patients, a finding which has 
previously been described (124,192). The increased mean cell 
haemoglobin concentration partly explained the reduced red cell 
deformability in diabetics but did not account for it completely.
Another determinant of red cell deformability is cell membrane fluidity, 
which may be related to the phospholipid bilayer (120) and membrane 
stiffening could therefore reflect alterations in serum lipids eg cholesterol 
(chapter 1). However the serum cholesterol level of the control group did 
not correlate with red cell filtration ratio. Lipid levels were not measured in 
the diabetic patients in this study, and therefore it is not possible to 
speculate whether the elevated levels of plasma lipids found in diabetes 
mellitus (89) could be related to impaired red cell filtration in the diabetic 
patients.
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At capillary level deformability of individual red cells is important if they are 
to pass through small diameter vessels. Filtration methods devised to 
stimulate this process in vitro have the main disadvantage of progressive 
clogging of the filters by sub-populations of rigid red and white cells. While 
the Carri-Med filtrometer is subject to some white cell contamination (165), 
it allows the clogging rate of the filter to be measured with time, and the 
initial filtration rate of the red cells can thus be extrapolated. Using this 
method there was a significant impairment in red cell deformability in 
diabetic patients compared to control subjects, this abnormality being 
worse in type 1 (insulin-dependent) diabetic patients.
Red cell deformability was unrelated to duration of diabetes or glycaemic 
control. Some previous studies have found impaired deformability to be 
related to glycaemic control (106,140) however incubating either diabetic or 
non-diabetic red cells with glucose to raise intracellular sorbitol levels 
produces only minor changes in deformability (118).
If internal cell changes or hyperglycaemia cannot account for the reduced 
red cell deformability in diabetics it seems likely that a membrane defect 
may be the major cause. Increased microviscosity of diabetic red cell 
membranes related to glycaemic control and insulin levels has been 
reported using fluorescent probes (120,121) and may be related to reduced 
spectrin phosphorylation or cross-linkage (127) or an imbalance of the 
cholesterol/phospholipid ratio (128).
Although it has been suggested that red cell deformability may be related to 
microvascular disease in diabetes (145,146) there have been few studies 
examining red cell deformability in diabetic patients with macrovascular 
disease. In this study red cell deformability was equally impaired in
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diabetic patients with microvascular complications, in patients with a 
combination of micro and macrovascular complications and in patients with 
no complications, which is in agreement with several previous studies of 
deformability in diabetic patients with microvascular disease (96,99,108). 
While reduced deformability may not be directly causative of micro- or 
macrovascular problems in diabetic patients, it could have a detrimental 
effect on ischaemic tissue, due to reduced blood flow in the disturbed 
microcirculation or in collateral vessels. It may also be a factor contributing 
to the early onset of vascular complications in diabetes mellitus. Further 
longitudinal studies are required to determine the relationship between red 
cell deformability, glycaemic control and onset of diabetic complications.
5.6 Summary
Red cell deformability through 5|im pores in normal healthy individuals was 
related only to mean cell volume. It is possible that conditions associated 
with macrocytic cells (such as hypothroidism, alcohol abuse or 
megaloblastic anaemia) may therefore be associated with reduced red cell 
filterability and this has indeed been suggested by other studies (193).
In diabetic patients red cell deformability assessed by filtration in this 
relatively new filtrometer was impaired when they were compared with non­
diabetic individuals, and this was partly related to mean cell haemoglobin 
concentration but may also be related to increased membrane rigidity.
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CHAPTER 6 
THE ROLE OF RHEOLOGICAL VARIABLES IN 
DIABETIC PERIPHERAL NEUROPATHY
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6.1 Introduction
Diabetic sensory peripheral neuropathy is generally accepted to have a 
metabolic origin, being related to hyperglycaemia and to duration of 
disease (194). Raised levels of intraneural sorbitol from increased activity 
of the polyol pathway and reduced levels of myoinositol and Na+/K + 
ATPase have been implicated in its pathophysiology (85,86). 
Nevertheless other diabetic complications such as retinopathy and 
nephropathy which are related to glycaemic control and duration of disease 
(63), are the result of microvascular abnormalites, and since there is an 
increased prevalence of microvascular disease in diabetic patients with 
sensorimotor neuropathy (195) it is possible that there may be a 
microvascular component leading to intraneural hypoxia in the 
development of neuropathy.
Simpson has suggested that alterations in haemorheological variables 
could be one mechanism contributing to decreased flow in nerve capillaries 
(146), but so far only abnormalities in platelet aggregation have been 
related to diabetic neuropathy (196). Whole blood viscosity and its 
determinants, including red cell deformability, was therefore measured in 
diabetic patients with symptomatic peripheral neuropathy and compared 
with a closely matched group of patients who had no evidence of 
neuropathy and with non-diabetic subjects selected from the healthy 
control population (chapter 5), to assess if diabetics with neuropathy have 
altered blood rheology.
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6.2 Patients
The three groups of patients studied were :
Group A which consisted of 29 diabetic out-patients (19 Male, 10 Female) 
with clinical evidence of chronic sensorimotor neuropathy of the lower limbs 
for more than six months duration. All patients had symptoms of pain 
and/or paraesthesia with nocturnal exacerbation together with signs of 
absent ankle reflexes, reduced or absent vibration perception to a tuning 
fork (128 Hz) and in some cases reduced cutaneous sensation to touch 
(n=12) or thermoreception (n=15). The patients all had normal peripheral 
arterial pulses and none had a history of excessive alcohol intake. 
Confirm ation of neuropathy was obtained in 18 patients; 
neurophysiological studies were performed on the common peroneal and 
sural nerves of the right lower leg using a Medelec Mystro MS6 machine. 
Compared to the laboratory normal range, conduction velocity was 
significantly reduced in both nerves in the diabetic patients and distal 
latency was significantly prolonged in the common peroneal nerve (Table
6.1).
Group B comprised 30 diabetic outpatients (20 Male, 10 Female) matched 
with group A patients for age (56 years-group A and 55 years-group B), sex 
(M/F; 19/20-group A and 20/10-group B) and glycaemic control (10.8 ± 
2.6%-group A and 10.9 ± 2.7%-group B). There were equal numbers of 
patients with type 1 diabetes (6 in each group), patients receiving insulin 
therapy (17 in each group) and patients with microvascular complications 
(13-group A and 12-group B), (Table 6.2). Diabetic patients in this group 
had no clinical evidence of neuropathy based on the criteria used to define 
neuropathy in group A making it unlikely that significant neuropathy was 
present.
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Table 6.1
Neurophysiology Studies
Value
Common Peroneal nerve:
Conduction velocity (m/s) 40.7± 4.3 a 
* Distal latency (ms) 7.6 ± 3.3 a
Sural nerve:
Conduction velocity (m/s) 31.4± 5.3 a
Distal latency (ms) 3.2±0.5
Normal
50.5±4.6  
3.6+0.5
48.3+5.3  
3.6+0.4
* Absent in 7 patients, 
a p <  0.001
Table 6.2
Characteristics of the groups
Group A Group B Group C
Sex ratio (M/F) 19/10 20/10 26/18
Smokers (n) 11 14 21
Age (yr) 56±10 55± 9 47± 8 3
Type 1 diabetes (n) 6 6 -
Insulin therapy (n) 17 17 -
Microvascular disease (n) 13 12 -
Body Mass Index (kg/m 2) 28.4+ 4.5 26.6± 3.9 26.4+ 4.0
Duration of diabetes (yr) 12±10 11±9 -
HbAi (%) 10.8±2.6 10.9+2.7 -
a p < 0.001
Group C was formed from 44 healthy volunteers (26 Male, 18 Female) free 
of painful or paraesthetic symptoms in their legs and with normal fasting 
blood glucose levels. They were matched with the diabetic patients with 
respect to sex ratio (M/F; 26/18) and body mass index (26.4 ± 4.0kg/m2) but 
were younger than the diabetic patients (47 years, p< 0.001), (Table 6.2).
6.3 Methods
6.3.1 Blood samples
Samples for viscosity, red cell deformability, haematocrit and red cell 
indices were measured in blood anticoagulated with dry potassium edetate 
(1.5mg/ml) within 2 hours of venesection. Whole blood viscosity was 
measured in the Contraves LS rotational viscometer (high shear-94.5s_1, 
low shear-0.945s"1) and plasma viscosity in a Coulter-Harkness capillary 
viscometer. Blood viscosity was corrected to standard microhaematocrit 
(Flawksley centrifuge) of 45% .
Red cell deformability was measured in the Carri-Med filtrometer (52) as 
described in the preceding chapter and chapter 3.5.
Mean cell volume was measured in the Coulter-S-Counter (normal range 
75-95 fl) and mean cell haemoglobin concentration was estimated as 
described (chapter 3.9). Fibrinogen was measured by the Clauss method, 
and glycated haemoglobin (HbA1) was measured by agar gel 
electrophoresis (Corning Glytrac).
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6.3.2 Statistical methods
Statistical methods utilised the Mann-Whitney U-test for difference in means 
and correlations between variables were analysed by the Spearman rank 
test. Results are expressed as mean ± SD.
6.4 Results
6.4.1 Viscosity
Corrected whole blood viscosity at both high and low shear rates was 
significantly higher in diabetic patients (5.29 ± 0.51 and 21.10 ± 3.03 
mPa.s) compared to control subjects (4.83 ± 0.54 and 17.36 ± 2.78 mPa.s, 
p<0.001), (Table 6.3). Low shear viscosity at native haematocrit was also 
elevated in the diabetic patients compared with control subjects (19.74 ± 
4.72 vs 17.36 ± 3.62 mPa.s, p<0.02). The higher whole blood viscosity in 
the diabetic patients was related to a higher plasma viscosity (1.41 ± 0.13) 
compared to the control subjects (1.29 ± 0.09 mPa.s, p<0.001) but there 
was no difference in protein levels (either fibrinogen or globulins) between 
diabetic patients or controls. Relative blood viscosity at low shear rates, 
was significantly higher in diabetic patients (15.12 ± 1.96) compared to 
control subjects (13.38 ± 2.02 mPa.s, p<0.001) and was similar in diabetic 
patients with neuropathy compared to those without neuropathy. No 
differences were found between diabetic patients with neuropathy and 
those without for whole blood viscosity, plasma viscosity or fibrinogen 
levels but globulin levels were significantly higher in the neuropathy group 
compared to the non-neuropathy group (Table 6.3).
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6.4.2 Red cell deformability
Red cell filtration was significantly reduced in both type 1 (0.456 ± 0.04) and 
type 2 diabetic patients (0.497 ± 0.04) compared to control subjects (0.550 
± 0.03 , p<0.01) and was significantly lower in type 1 compared to type 2 
diabetic patients (difference 0.04, 95% Cl; 0.02 to 0.06, p<0.02). There was 
no difference in red cell filtration rates between diabetic patients with 
neuropathy and those without neuropathy (0.490 ± 0.05 vs 0.490 ± 0.04 , 
p>0.05), (Figure 6.1).
There was a significant inverse correlation of red cell filtration ratio with 
mean cell haemoglobin concentration (r=-0.29, p<0.01) but no correlation 
of filtration ratio with other haematological variables, glycaemic control, age 
or duration of diabetes was found.
6.5 D iscussion
It has long been thought that persistent hyperglycaemia was responsible for 
the nerve damage sustained in diabetes and correlations have been shown 
between both fasting blood glucose and glycated haemoglobin levels and 
conduction velocities of motor nerves (195,197) and with vibration sense 
(198). There is also evidence that improving glycaemic control with 
treatment using continuous subcutaneous insulin infusions over a period of 
several months can alleviate the symptoms of neuropathy and improve 
conduction velocity (199).
Mechanisms thought to be involved in the metabolic aetiology of 
neuropathy include increased activity of the polyol pathway leading to 
raised levels of insoluble sorbitol and fructose within nerve cells and a
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GROUP C GROUP A
mean, 2 SD
p < 0.01
GROUP B
Figure 6.1
Red cell filtration ratios in control subjects
and diabetic patients with and without neuropathy
consequent fall in levels of myoinositol and Na+/K+ ATPase (85). While 
increased concentrations of sorbitol have been found in diabetic nerves at 
biopsy, alterations in myoinositol within the nerve remain controversial (86). 
Several studies in diabetic patients using aldose reductase inhibitor drugs 
appear to improve both symptoms of neuropathy and conduction velocities 
of specific nerves (200,201).
Fagerberg in 1959 described intraneural vascular lesions in diabetic 
nerves such as a reduction in capillary size with thickening of the walls, 
hyalinisation and deposition of PAS positive material (202). Endoneurial 
capillary disease could therefore be a manifestation of the generalised 
microangiopathy of diabetes mellitus and due to disruption of blood flow 
could be responsible for hypoxic nerve damage and thus neuropathy. 
Since these observations, further intraneural abnormalities have been 
described in diabetic patients with a history of neuropathy; capillary 
plugging with fibrin and thrombus (203,204) and capillary closure due to 
endothelial hyperplasia and desquamation (205,206). In addition it has 
been suggested that the pattern of nerve fibre loss in diabetic neuropathy 
has an ischaemic origin (207). In support of this theory Newrick et al have 
demonstrated reduced oxygen tension within the sural nerve of diabetic 
patients suffering from neuropathy (208).
Diabetic patients have rheological abnormalities including an increase in 
whole blood viscosity, plasma viscosity, red cell aggregation and a 
reduction in red cell deformability (185). The disturbance in blood flow 
behaviour has been shown to be more abnormal in patients with 
proliferative retinopathy (99) and microalbuminuria (108) and this could be 
one mechanism leading to reduced flow and sludging of blood within 
intraneural capillaries in diabetic patients with neuropathy. I sought to
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determine if patients with diabetic neuropathy could have significant 
alterations in blood viscosity or its determinants or in red cell deformability 
compared to patients without neuropathy, which could explain the finding 
of intraneural ischaemia in diabetic neuropathy.
Although a significant increase in viscosity at high and low shear rates and 
a reduction in red cell deformability in the diabetic patients as a whole was 
found, I was unable to demonstrate differences in these variables between 
patients with neuropathy and those without. It may be argued that 
subclinical neuropathy was not definitely excluded in patients from group B, 
but since there was little doubt that patients in group A had clear evidence 
of neuropathy based on clinical findings (209), with confirmation of large 
fibre damage as shown by impaired conduction velocities, it is extremely 
unlikely that patients in group B had nerve damage comparable to that of 
group A.
It is of interest that patients with neuropathy had higher levels of serum 
proteins (other than fibrinogen) compared to patients without neuropathy, 
because large serum proteins such as oc2-macroglobulin would be 
expected to give rise to greater red cell aggregation (57), a parameter 
which is indirectly measured by low shear whole blood viscosity. I found no 
difference in viscosity at these shear rates between the two groups, but 
more sensitive apparatus such as the Myrenne aggregometer may be able 
to detect more subtle differences (142).
These findings, although negative, do not exclude abnormal rheology from 
contributing to nerve ischaemia by acting as a cofactor with intraneural 
microvascular abnormalities (210) to reduce blood flow in capillaries and
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enhance thrombus formation. Increased erythrocyte adhesion to 
intraneurial capillary endothelial cells in diabetes (130) may be a factor 
reducing capillary luminal diameter, and it also remains possible that the 
presence of wider channel arterio-venous shunts in the vicinity of the nerve 
caused by coincidental autonomic neuropathy (211) could favour the 
diversion of more viscous diabetic blood from the smaller calibre nutritive 
capillaries.
6.6 Summary
Thus the current evidence for microangiopathy in diabetic neuropathy is 
strong, but it seems unlikely that altered rheology in diabetes per se is 
directly responsible for endoneurial hypoxia. Capillary structural 
abnormalities in conjunction with alterations in rheology may however lead 
to nerve ischaemia and along with metabolic factors result in neuropathy.
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CHAPTER 7
ASSESSMENT OF RED CELL AGGREGATION IN 
NON-DIABETIC VOLUNTEERS AND ASSOCIATION 
WITH VASCULAR COMPLICATIONS IN 
DIABETES MELLITUS
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7.1 Introduction
The mechanism leading to aggregation of red cells is not entirely clear, but 
many molecules in the red cell membrane have charged head groups 
which under normal circumstances amounts to an overall negative charge 
due mainly to sialic acid residues (212). Repulsive electrostatic forces 
therefore exist between red cells, which dominate over the weaker 
attraction of the Van der Waal's forces causing a net repulsion (213). The 
force causing aggregation of red cells must be greater than the repulsive 
forces: this is achieved by the formation of protein bridges between cells 
created by long-chain proteins adhering to cells at either end.
The most important plasma protein causing red cell aggregation is 
fibrinogen, this being a large, elongated and flexible molecule (length 40 
nm, molecular weight 340 000). However it is not known what holds 
fibrinogen to the cell membrane although its adsorption is probably 
influenced by electrostatic forces (27). Other proteins with high molecular 
weights will also cause aggregation and it has been suggested that some 
of these proteins may enhance the aggregating effect of fibrinogen (24).
Rouleaux formation is dependent on shear rate (23): as the shear rate falls 
the bulk viscosity of blood will increase due partly to red cell aggregation 
(chapter 1). As shear rate increases viscosity falls until rates of about 100/s, 
when the aggregates will be totally dispersed. Rouleaux formation affects 
blood flow in both large and small vessels; in the centre of large vessels, 
the shear rate is low and thus increased viscosity associated with rouleaux 
formation will occur, while in microvessels aggregation will be enhanced 
due to low shear rates in post capillary venules. An increase in haematocrit 
or serum proteins will increase the extent of aggregation and could
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potentially reduce flow in these small vessels.
High levels of fibrinogen may reflect the acute or chronic stress responses 
which are the body's response to injury, infection or inflammation. They are 
thought to involve stimulation of monocyte production of Interleukin by fibrin 
degradation products D and E. This causes both hepatic synthesis of acute 
phase proteins and release of platelets and white blood cells from bone 
marrow. Fibrinogen is the most important acute phase protein, and many 
studies have found raised levels in diabetic patients, possibly due to 
increased hepatic synthesis (214). The chronic stress response in 
diabetes (131) could therefore lead to increased red cell aggregation in 
vivo.
There have been few studies measuring red cell aggregation directly in 
diabetic patients, but using instruments such as the rheophotometer (96), 
rheoscope (136) and syllectometry (135) aggregation has been found to be 
raised in diabetes, usually in association with raised levels of plasma 
proteins e.g. fibrinogen, a 2 and (3-globulins. Because increased 
aggregation leads to raised blood viscosity and hence to reduced blood 
flow and possibly vascular stasis, particularly in post-capillary venules, it 
can be postulated that this could contribute to tissue ischaemia and the 
increased incidence of vascular complications in diabetes. The main 
diabetic complication which has been studied in relation to red cell 
aggregation is diabetic retinopathy, and the results of previous studies have 
been conflicting, with some workers finding no difference in red cell 
aggregation between patients with retinopathy and those without (96,135), 
and others who found a correlation between the extent of aggregation and 
severity of retinopathy (136,215).
This study was undertaken to compare red cell aggregation, measured by a
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new simple technique, in diabetic patients with non-diabetic healthy 
individuals and to assess mainly the effects of glycaemic control, type of 
diabetes, and whether vascular complications or hypertension in diabetes 
are associated with higher levels of aggregation.
Triglyceride's carrier protein, very low density lipoprotein (VLDL) is a large 
plasma protein (having a diameter of 30-80nm), which could in theory also 
have an effect on red cell aggregation by creating protein bridges, but to 
date this has not been studied in any population sample. Diabetic patients 
generally have higher levels of serum lipids and lipoproteins (89) 
compared with non-diabetic subjects and it was aimed to examine the 
relationship between plasma lipids and red cell aggregation in both 
diabetic and non-diabetic control subjects, to determine if this could be a 
factor contributing to the reported increased red cell aggregation in 
diabetes mellitus.
7.2 Patients
7.2.1 Diabetic Patients
110 diabetic patients were selected from the out-patient clinic (54 type 1, 
insulin-dependent and 56 type 2 non-insulin dependent). Sex ratio of the 
type 1 diabetics was 22 male and 32 female, and of the type 2 diabetics 
was 29 male and 27 female. Mean age of the type 1 patients was 38 years 
(range 17-65 years) and 59 years in the type 2 patients (range 43-73 
years), p < 0.001.
Therapy in the type 2 diabetics consisted of insulin in 26 patients, orafl 
hypoglycaemic agents in 2 9 patients and dietary therapy in 7 patients. The
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type 1 diabetics had significantly longer duration of diabetes (19 ± 10 
years) compared with the type 2 diabetics (9 + 6 years, p < 0.001) and 
significantly lower body mass index (23.8 ± 3.2 kg/m2) compared with type 
2 diabetics (28.3 ± 5.2 kg/m2, p < 0.001). Both groups of patients were 
matched for glycaemic control as measured by blood glucose (11.9 ± 
6.2mmol/l-type1 v 12.3 ± 5.1 mmol/l-type 2, p>0.05) and glycated 
haemoglobin (10.8 ± 2.1%-type1 v 10.4 ± 2.1%-type 2, p>0.05), (Table 7.1). 
Macrovascular disease was said to be present if patients had evidence of 
ischaemic heart disease, cerebrovascular disease or peripheral vascular 
disease. Microvascular disease was scored as 0 for no complications, 1 for 
background diabetic retinopathy, 2 for pre-proliferative or proliferative 
retinopathy and 3 for retinopathy plus nephropathy.
Of the type 1 diabetics two had macrovascular disease, while 15 of the type 
2 diabetics had macrovascular complications, five of whom were 
hypertensive. Microvascular complications were present in 33 type 1 
diabetics and 36 type 2 diabetics.
7.2.2 Control subjects
100 healthy non-diabetic control subjects were chosen to match as closely 
as possible with the diabetic patients for age and sex distribution. They 
were divided into two groups of 50 subjects to compare with the type 1 and 
the type 2 diabetics. Mean age of group 1 was 34 years (range 21-48 
years) and of group 2 was 59 years (range 45-87 years), p < 0.001. The 
two groups were matched for body mass index (23.0 ± 3.8kg/m2-group 1 vs
24.6 ± 4.7kg/m2-group2, p>0.05) and consisted of 21 males, 29 females in 
group 1 and 23 males, 27 females in group 2, (Table 7.1).
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Table 7.1
Characteristics of the groups
Diabetics Controls
Type 1 Type 2
n 54 56 100
Age (yr) 38± 13 59 ± 7 a 4 7 ± 1 6 b,c
Body Mass Index (Kg/m 2 ) 23.8± 3.2 28.3 ± 5.2 a 23.9 ±4.3
Sex (M/F) (22/32) (29/27) (44/56)
Duration of diabetes (yr) 19± 10 9+  6 a -
Blood Glucose (mmol/l) 11.9± 6.2 12.3 ±5.1 -
HbAi (%) 10.8± 2.1 10.4 ± 2.1 -
[NR 5.5 - 8.5%]
Values are mean ± SD
a p < 0.001 Type 2 v Type 1 diabetics 
b p < 0.001 Controls v Type 2 diabetics 
c p < 0.02 Controls v Type 1 diabetics
7.3 Methods
7.3.1 Blood samples
Red cell aggregation was assessed in the Myrenne red cell aggregometer 
(chapter 3.7). Briefly, 25 pi of whole blood was dropped onto the centre of 
the cone and the sample spun at 600 s-1 before being stopped abruptly. 
The extent of aggregation, determined as the change in light transmission 
over 5 seconds of stasis, was recorded digitally as the aggregation index. 
The mean of two readings was taken then a further assessment was made 
on a further sample adjusted to a haematocrit of 40%.
Microhaematocrit was measured with the Hawksley centrifuge and reader, 
and red and white cell indices on the Coulter-S-Counter. Plasma viscosity 
was measured on 1ml of plasma in the Coulter-Harkness capillary 
viscometer (3.3).
Plasma lipoproteins were measured on the Hitachi 704 analyser 
(Boehringer Mannheim, FRG) after density gradient separation by 
ultracentrifugation on a Beckman centifuge.
Total proteins, albumin and globulin were measured by SMAC (Technicon, 
Basingstoke). Fibrinogen was measured by the heat precipitation method 
(chapter 3.8) and haptoglobin and macroglobulin by immunoturbidimetric 
analysis on the Encore analyser (Baker Instruments, Pennysylvania).
Blood glucose was measured by the hexokinase method on a Hitachi 737 
analyser and glycated haemoglobin by agar gel electrophoresis (Corning 
Glytrac).
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7.3.2 Urinary protein
Microproteinuria excretion was measured by radioimmunoassay as 
albumin excretion rate (AER) and macroproteinuria excretion as total 
protein excretion per volume in 24 hours. Urinary protein values of 
between 20 and 200mg/l were accepted as microproteinuria and values of 
> 200mg/l as macroproteinuria.
7.3.4 Physical variables
Blood pressure was measured by an electronic sphygmomanometer 
(Neissi, Japan) and values greater than 160/95 mmHg were accepted as 
hypertension. Values less than this were accepted as hypertension if the 
patients were taking specific anti hypertensive treatment. Body mass index 
was estimated from weight (kg) divided by height squared (m2).
7.3.5 Statistical methods
The Mann-Whitney U-test was used for comparison of means between 
diabetic patients and controls and within the two groups. Spearman rank 
correlation was used to determine the association between red cell 
aggregation index and variables.
7.4 Results
No difference was found in red cell aggregation measured at native 
haematocrit or at 40% haematocrit in any of the groups of patients studied, 
and all the following results of red cell aggregation index are therefore
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given for haematocrit of 40%.
7.4.1 Control subjects
Red cell aggregation index was similar in male subjects (3.4 ± 1.4) 
compared with female subjects (3.2 ± 1.2, p>0.05) and in smokers (3.2 ±
1.2) compared with non-smokers (3.4 ±1.1, p>0.05).
There was a significant correlation of red cell aggregation index with 
triglyceride level (r=0.21, p<0.02), fibrinogen level (r=0.26, p< 0.02) and 
a 2-macroglobulin level (r=-0.30, p<0.02) and an inverse correlation with 
mean cell volume (r=-0.19, p<0.05), Table 7.2.
7.4.2 Diabetic patients 
(i) Type of diabetes:
Red cell aggregation index was significantly increased in type 2 diabetic 
patients compared with type 1 (at corrected haematocrit; 5.5 ± 1.5 vs 4.3 ± 
1.3, p<0.001), Figure 7.1. Fibrinogen level was higher in type 2 diabetics 
(4.1 ± 1.2g/l) compared with type 1 diabetics (3.5 ± 1.2g/l, p<0.03) while ot2~ 
macroglobulin levels were significantly higher in type 1 diabetics (2.46 ± 
0.70g/l) compared with type 2 diabetics (1.71 ± 0.66g/l, p<0.001), (Table
7.3).
Triglyceride and VLDL levels were significantly higher in type 2 diabetics 
(2.64 ± 1.80 mmol/l and 1.06 ± 0.68 mmol/l) compared with type 1 diabetics 
(1.49 ± 1.16 mmol/l, p<0.002 and 0.59 ± 0.34 mmol/l, p<0.001) and HDL 
levels were significantly lower in the type 2 diabetics (1.24 ± 0.41 mmol/l) 
compared with the type 1 diabetics (1.44 ± 0.39 mmol/l, p< 0.02), Table 7.4. 
In both type 1 and type 2 patients red cell aggregation index correlated with
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Table 7.2
Correlation of red cell aggregation with variables 
in control subjects.
V a riab le  rs
Age (yr) - 0.07
Body mass index (kg/m2 ) 0.16
Plasma viscosity (mPa.s) 0.11
Haematocrit (%) - 0.15
Mean cell volume (fl) - 0.19 b
Globulin (g/l) 0.26a
Fibrinogen (g/l) - 0.04
a 2 macroglobulin (g/l) - 0.30 3
Haptoglobin (g/l) - 0.17
Triglyceride (mmol/l) 0.21 a
Cholesterol (mmol/l) - 0.12
VLDL (mmol/l) 0.11
LDL (mmol/l) - 0.04
HDL (mmol/l) -0.08
a p <0.02 
b p <0.05
8 1  
7 -
6 -  
5 -  
4 -
3 -  
2 -  
1 -
•  Diabetic Patients 
O Control subjects
p< 0.002
()
p< 0.0001
p< 0.0001
o
Type 1 Type 2
Values are mean ± SD
Figure 7.1
Red cell aggregation index in diabetic patients and 
control subjects
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plasma triglyceride level (r=0.36 and r=0.41, p<0.001), VLDL level (r=0.26 
and r=0.30, p<0.02) and HDL level (r=-0.26 and r=-0.30, p<0.02). However 
there was no significant association wth other plasma proteins i.e. 
fibrinogen, a 2-macroglobulin, haptoglobin or with globulin/albumin ratio, 
Table 7.5. Correlation of red cell aggregation with VLDL is shown in Figure 
7.2.
In the type 2 patients there was a significant inverse correlation with 
duration of diabetes (r=-0.24, p<0.05) and a positive correlation with body 
mass index (r=0.30, p<0.02).
Within the type 2 diabetics there was no difference in red cell aggregation 
between patients receiving insulin therapy and those receiving oral 
hypoglycaemic agents or dietary therapy alone (5.2 ± 1.5 vs 6.1 ± 1.5 vs
5.4 ±1.3, p>0.05).
(ihType 1 diabetics and controls
Red cell aggregation index was significantly higher in the diabetic patients 
(4.3 ± 1.3) compared with the control subjects (at corrected haematocrit, 3.4 
± 1.2, p<0.002), Figure 7.1.
Plasma viscosity was significantly higher in diabetics compared with the 
controls (1.35 ± 0.97 vs 1.27 ± 0.06 mPa.s, p<0.001). The globulin/albumin 
ratio was higher in diabetic patients compared with controls (0.59 ± 0.12 vs 
0.52 ± 0.10, p<0.01) and all three plasma proteins measured were 
significantly higher in the diabetics compared with the controls (fibrinogen,
3.5 ± 1.2 vs 2.8 ± 0.9 g/l, p<0.01; haptoglobin, 1.48 ± 0.57 vs 0.91 ± 0.35 g/l, 
p<0.001; a2-macroglobulin, 2.46 ± 0.70 vs 1.63 ± 0.58 g/l, p<0.001)), (Table
7.3) Of the lipids only triglyceride level was significantly different in diabetic 
patients compared with control subjects (1.49 ± 1.16 vs 1.05 ± 0.42 mmol/l, 
p<0.01), (Table 7.4).
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Table 7.5
Correlation of red cell aggregation with variables in 
diabetic patients (rs values)
Type 1 Type 2
Age (yr)
Body mass index (kg/m2 ) 
Duration of diabetes (yr) 
HbA-j (%)
Blood glucose (mmol/l) 
Plasma viscosity (mPa.s) 
Mean cell volume (fl) 
Globulin (g/l) 
Globulin/Albumin ratio 
Fibrinogen (g/l) 
a 2 macroglobulin (g/l) 
Haptoglobin (g/l) 
Triglyceride (mmol/l) 
Cholesterol (mmol/l) 
VLDL (mmol/l)
LDL (mmol/l)
HDL (mmol/l)
- 0.16 - .0.07
0.15 0.30b
- 0.18 - 0.23°
- 0.19 0.07
0.16 - 0.02
- 0.19 - 0.09
0.19 - 0.05
- 0.06 0.01
- 0.17 0.06
- 0.03 -0.17
- 0.11 - 0.15
0.17 - 0.01
0.36 a 0.41 a
0.07 - 0.08
0.26 b 0.30b
0.04 - 0.13
-0 .26° - 0.30b
a p < 0.001 
b p < 0.02 
c p < 0.05
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Figure 7.2
Correlation of red cell aggregation index with VLDL in 
diabetic patients
(iii) Type 2 diabetics and controls
Red cell aggregation index was significantly higher in the diabetic patients 
compared with the controls (5.5 ± 1.5 vs 3.2 ± 1.3, p<0.001), Figure 7.1. 
Plasma viscosity was significantly higher in the diabetics compared with 
controls (1.38 ± 0.10 vs 1.30 ± 0.11, p<0.001) as was fibrinogen level (4.1 ±
1.2 vs 3.3 ± 0.8 g/l, p<0.01) but a2-macroglobulin levels were significantly 
lower in the diabetics (1.71 ± 0.66 vs 2.33 ± 0.50 g/l, p<0.001). Both 
triglyceride and VLDL levels were higher in the diabetic patients compared 
with the controls (2.64 ± 1.80 vs 1.23 ± 0.59 mmol/l, p<0.001 and 1.06 ± 
0.68 vs 0.59 ± 0.22 mmol/l, p<0.01) and the HDL level was significantly 
lower (1.24 ± 0.41 vs 1.68 ± 0.42 mmol/l, p<0.001), Table 7.4.
(iv) Effect of hypertension
Mean blood pressure in the hypertensive patients was 163 ± 29/89 ± 15 
mmHg which was significantly higher than in the normotensive patients 133 
± 20/76 ± 9mmHg, p<0.001. Since type 1 and type 2 diabetic patients had 
differences in red cell aggregation and several other variables they were 
assessed separately for differences in red cell aggregation between 
hypertensive and normotensive patients.
There was no significant difference in red cell aggregation index between 
patients with hypertension (n=9; 4.3 ± 1.4) and patients without 
hypertension (n=42; 4.3 ± 1.4) in the type 1 diabetics whereas in the type 2 
diabetics red cell aggregation index was significantly higher in patients with 
hypertension (n=15; 6.3 ± 1.8) compared to those without (n=40; 5.2 ± 1.3, 
p<0.02), Figure 7.3.
In the type 2 group the only variable which was significantly different 
between the hypertensive and normotensive patients was body mass index 
(31.0 ± 5.2 vs 27.1 ± 4.8 kg/m2, p<0.02).
Both diastolic and systolic blood pressure correlated with red cell
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Red cell aggregation in hypertensive and 
normotensive type 2 diabetic patients
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Figure 7.4
Correlation of red cell aggregation index with 
diastolic blood pressure in type 2 diabetic patients
aggregation in the diabetic population, (Table 7.5) but in the type 2 diabetic 
patients only diastolic blood pressure correlated with red cell aggregation 
index (r=0.23, p<0.02, Figure 7.4).
(v) Effect of macrovascular and microvascular complications 
The effect of macrovascular disease was not examined in the type 1 
diabetic patients because only two patients had evidence of large vessel 
complications. Within the type 2 diabetic patients 15 had macrovascular 
disease and because red cell aggregation was higher in type 2 patients 
with hypertension these were analysed separately from normotensive type 
2 patients. Red cell aggregation index was significantly higher in the 
hypertensive diabetics with macrovascular disease (7.8 ± 1.2) compared 
with hypertensive diabetics without macrovascular disease (5.6 ± 1.6, 
p<0.02). In the normotensive patients red cell aggregation index was 
similar in patients with macrovascular disease (5.1 ± 1.3) and those without 
(5.2 ±1.3, p>0.05).
The association between microvascular disease and red cell aggregation 
was assessed in the type 1 diabetics as a whole because there was no 
difference in those with hypertension and those without and because there 
were only 9 patients with hypertension. In the type 2 patients differences in 
red cell aggregation between the various microvascular groups were 
assessed both for the type 2 patients as a whole and for the subgroup of 
patients without microvascular disease. The numbers in each 
microvascular category for patients with hypertension were too small to 
allow statistical comparisons. Within the type 1 diabetics there was no 
difference in red cell aggregation index between patients with no 
complications and those with background retinopathy (4.1 ± 1.2 vs 3.7 ±
1.1, p>0.05) but the value was significantly higher in patients with
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Table 7.6
Association of red cell aggregation with 
microvascular complications
Type 1 
diabetics
Type 2 
diabetics
No complications 4.1± 1.2 5.2±1.1
Background
retinopathy
3.7± 1.1 5.2±1.4
Proliferative
retinopathy
5.2±1.3a 5.612.0
Retinopathy and 
nephropathy
4.3+1.5 6.811.1
a p <0.02, type 1 diabetic patients with proliferative
retinopathy v type 1 patients with background 
retinopathy.
proliferative retinopathy (5.2 ± 1.3) compared to those with background 
changes (3.7 ±1 .1 , p<0.02). However there was no difference between 
patients with retinopathy and nephropathy and the other groups (4.3 ± 1.5). 
In type 2 diabetics as a whole although the red cell aggregation index 
increased with increasing severity of complications the difference between 
patients with no complications and those with background or proliferative 
retinopathy was not significant (5.2 ±1.1 vs 5.2 ± 1.4 vs 5.6 ± 2.0 vs 6.8 ±
1.1, p>0.05), (Table 7.6). When the non-hypertensive diabetics were 
assessed the results were similar (no complications - 5.1 ± 1.0, 
background retinopathy - 5.3 ± 1.3 , proliferative retinopathy - 5.1 ± 1.7, 
p>0.05). Only one normotensive type 2 patient had retinopathy and 
nephropathy and this group was therefore insufficient for comparison.
7.5 Discussion
This study found increased levels of fibrinogen in both type 1 and type 2 
diabetic patients compared to their matched controls, and in the type 1 
diabetics raised levels of haptoglobin and a2-macroglobulin compared with 
controls, as would have been expected from previous reports of these 
proteins in diabetics (100) although they did not correlate with red cell 
aggregation as might have been predicted. Interestingly a2-macroglobulin 
level was lower in the type 2 patients compared with their matched controls. 
There is no obvious explanation for this finding, but perhaps it is due to 
alterations in the balance of plasma globulin levels in type 2 diabetics, 
because the globulin/albumin ratio was similar in type 2 diabetics 
compared with controls, in contrast to type 1 diabetics where the ratio was 
higher compared with controls, (Table 7.3).
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There was an increased level of triglyceride in type 1 diabetic patients and 
increased levels of triglyceride and VLDL with lower levels of HDL in type 2 
diabetic patients compared with non-diabetics. Previous studies have 
suggested that type 1 diabetics often have similar levels of plasma lipids to 
non-diabetic controls if well-controlled (216), whereas type 2 diabetics have 
increased lipid levels compared with type 1 diabetics (217) and can have 
levels of 50-100% greater than those of non-diabetics (218). In particular 
diabetics have higher levels of triglyceride and VLDL and lower levels of 
HDL (219). There appears to be increased production and decreased 
removal of triglyceride in type 2 diabetics leading to increased VLDL 
production (220) and in type 1 diabetics there is reduced clearance of 
VLDL, possibly due to decreased lipoprotein lipase activity as a result of 
insulopenia (221). Why VLDL production is high remains unclear but it may 
be secondary to relative cellular insulopenia in the presence of 
hyperinsulinaemia or due to raised non-esterified fatty acid production 
(222). Qualitative changes in VLDL have also been suggested, viz. 
triglyceride enrichment leading to increased size of VLDL molecules (223), 
alterations in apoproteins (224) or glycosylation of apoproteins leading to 
reduced clearance of VLDL (225). HDL is formed from the hydrolysis of 
VLDL and insulin deficiency has been blamed for reduced production of 
HDL in type 1 diabetes (226) and there is thought to be an inverse 
relationship between plasma insulin level and HDL levels in type 2 diabetic 
patients (227).
Red cell aggregation was increased in diabetic patients compared with 
non-diabetic individuals, confirming the findings of previous workers but in 
this study in a much larger group of patients than has been reported before. 
Although aggregation of red cells is most commonly related to plasma 
protein levels, particularly fibrinogen, this was found to be the case only in
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the non-diabetics, despite fibrinogen levels being higher in the diabetics. 
In non-diabetics aggregation was also related to red cell size, as expected 
(28) but in addition was correlated with plasma triglyceride level which has 
not previously been described. In the diabetic patients the extent of red cell 
aggregation not only correlated with triglyceride level but also with VLDL 
and (inversely) with HDL levels. These findings support the theory that 
lipoproteins may be capable of aggregating red cells, and in the case of 
diabetics (especially the older type 2 diabetics where the plasma lipid 
levels are high compared with non-diabetics), this could be a major factor 
determining increased red cell aggregation. The Framingham study 
showed that diabetic patients have an increased morbidity and mortality 
from vascular diseases (90) and further analysis of the data revealed that 
triglyceride was an independent risk factor for ischaemic heart disease in 
diabetics, especially in the presence of a low HDL level (228). In the WHO 
multinational study, triglyceride was also found to correlate with ischaemic 
heart disease in several of the centres studied, especially in obese non­
insulin-dependent diabetics (219). Thus the raised triglyceride and VLDL 
levels in diabetes, as well as being an independent risk factor for 
cardiovascular disease could also contribute to vascular complications by 
increasing red cell aggregation and leading to reduced flow, stasis or even 
thrombosis in low shear conditions in blood vessels.
In type 2 diabetic patients the degree of red cell aggregation was related to 
body mass index and inversely to duration of diabetes, possibly because 
the shorter the duration of disease the less the extent of weight loss and 
thus the less likely that good glycaemic control had been established. 
Triglyceride level tends to be higher in newly diagnosed diabetics (229) 
and in this study triglyceride was inversely related to duration of diabetes 
(r=-0.30, p<0.001).
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When the relationship between hypertension and red cell aggregation was 
studied no effect was observed in type 1 diabetic patients, although the 
number of patients with hypertension in this group was small. However in 
type 2 diabetic patients red cell aggregation was higher in hypertensive 
patients and was positively correlated with blood pressure. Hypertension 
has been associated with rheological disturbance in non-diabetic subjects 
(160,177) and one previous study has found whole blood viscosity at low 
shear rates to be higher in hypertensive type 2 diabetic patients (185) 
which would be in keeping with the findings for red cell aggregation in the 
present study. Hypertension is common in type 2 diabetes (160,179) and 
is a cardiovascular risk factor in diabetes (91). The increased red cell 
aggregation of diabetes and of hypertension may be additive and relevant 
to the increased incidence of macrovascular disease in hypertensive 
diabetics. In a study of non-diabetic patients cardiovascular disease was 
shown to correlate with red cell aggregation level and it was suggested that 
red cell aggregation may be a prognostic indicator for ischaemic heart 
disease (230). In support of this hypothesis this study found that red cell 
aggregation was higher in hypertensive type 2 diabetics with 
macrovascular disease compared with hypertensive type 2 diabetics who 
had no evidence of macrovascular disease, although the numbers in each 
group were small. Triglyceride and VLDL levels were higher and HDL 
levels lower in the hypertensive diabetics, and although the difference was 
not significant when compared with the normotensive patients, possibly due 
again to the relatively small number of patients with hypertension, 
increased lipids in hypertensive diabetics may nevertheless be a 
contributing factor to the enhanced red cell aggregation.
Hypertension has also been demonstrated as a risk factor for microvascular 
complications (182,184) but the number of patients with hypertension and
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microvascular disease was too small to allow comparison of red cell 
aggregation between patients with and those without hypertension. 
However it was possible to examine the association of red cell aggregation 
with microvascular disease in both type 1 and type 2 diabetics. Within the 
type 2 patients there was no difference in red cell aggregation whether 
microvascular disease was present or not, the extent of aggregation being 
higher in all groups compared with type 1 diabetics with similar 
complications. Type 1 diabetics on the other hand appeared to have 
increased red cell aggregation in the presence of proliferative retinopathy 
but there was no additive effect of nephropathy. Ditzel's study showed 
similar results (133), and it is only possible to speculate why the increasing 
severity of microvascular damage is not associated with increased red cell 
aggregation - perhaps alterations in plasma proteins due to protein loss in 
nephropathy prevent excessive aggregation.
7.6 Summary
Red cell aggregation is increased in diabetic patients and is influenced by 
the type of diabetes. The greater extent of aggregation in type 2 diabetics 
per se seems to override the increased red cell aggregation of 
microvascular disease seen in type 1 patients. Aggregation in diabetes is 
related to plasma lipids and the higher lipoproteins in type 2 patients may 
account for the increased red cell aggregation in this group. High levels of 
lipoproteins may also contribute to the increased aggregation seen in type 
2 hypertensive diabetics. The increased incidence of macrovascular 
disease in diabetes could be related to increased red cell aggregation 
leading to alterations in blood flow which in combination with structural 
changes in blood vessels (e.g. due to atheromatous plaques) result in
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tissue hypoxia and subsequent organ damage. The increased triglyceride 
and VLDL levels in diabetes may therefore indirectly contribute to vascular 
complications by an effect on red cell aggregation. Thus overweight type 2 
diabetics with hypertriglyceridaemia (particularly with low HDL levels) are 
at the greatest risk of complications related to increased red cell 
aggregation and patients with concomitant hypertension will be further 
compromised.
To investigate these findings further, longitudinal studies of red cell 
aggregation in diabetic patients with hypertension and vascular disease 
are required and it would be of interest to measure red cell aggregation in 
diabetic patients with different types of hyperlipoproteinaemia.
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CHAPTER 8
FILTERABILITY OF WHITE BLOOD CELL
SUBPOPULATIONS IN DIABETES
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8.1 Introduction
White blood cells have a similar diameter to red blood cells (6-7 pm- 
lymphocytes, 7-7.5 pm- granulocytes, compared to 7.5 pm for red cells) but 
deform less readily than red blood cells due to their greater intracellular 
viscosity (about three times that of red blood cells) and spherical shape 
(158), Table 8.1. They can however pass through capillaries with 
diameters as small as 2.6-2.8 pm as with red cells, but deformation takes 
longer and the force required is about four to five times that necessary to 
deform a red blood cell (30).
Rheological influence of white blood cells on flow resistance is negligible in 
large vessels because of the low white cell concentration in normal blood 
(7 million/ml i.e. 1/700 of red cells) and they account for < 1% of the total 
volume of blood cells and contribute little to the bulk viscosity of blood. It is 
in capillaries with diameters less than 5 pm that the white cell exerts its 
greatest effect on flow resistance (231) and where rheological properties of 
different white cell subpopulations are most important.
White blood cell subpopulations differ in their rheological properties as 
shown by both filtration studies and micropipette studies (31,32,232), 
mononuclear cells being less deformable than polymorphonuclear cells, 
and monocytes being less deformable than lymphocytes.
White blood cells have a large effect on the distribution of red cells at 
capillary level and the interaction of red and white blood cells will thus 
determine oxygen delivery to tissue cells. Entrance of a white cell into a 
capillary branch will increase the resistance and decrease the flow in that 
branch causing preferential entry of the subsequently arriving twenty to
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Table 8.1
Rheological properties of neutrophils and erythrocytes
erythrocytes neutrophils
Time constant for initial deformation (msec) 20 - 120 650
Cellular viscosity (Pa.s) 7 1300
From: Chien S. White blood cell rheology: Clinical Blood Rheology (ED GDO Lowe) 1988:96
thirty red cells into another branch. As red blood cells leave capillaries to 
enter venules they overtake white cells forcing the latter towards the vessel 
wall (233) and because the post-capillary venules have the lowest shear 
stress in the circulation (234) the rouleaux formation from red cell 
aggregation will also tend to displace the white cells towards the vessel 
wall (33). There are therefore two mechanisms which cause margination of 
white cells. At the vessel wall white cells may interact with the endothelium 
to cause adhesion which will be important for extravasation, but which 
could also cause narrowing of the vessel diameter and a further increase in 
flow resistance by large immobile white cells (34), this is particularly the 
case with granulocytes (44). In addition white cell adhesion and activation 
in ischaemia could lead to endothelial damage due to the release of toxic 
oxygen compounds and proteolytic enzymes (33).
An increase in white blood cell count or a decrease in white cell 
deformability could further reduce flow in microvessels and lead to tissue 
hypoxia, and as the flow rate is reduced the leucocyte-related obstruction 
increases in a cycle which may lead to capillary closure.
In diabetic patients interaction between the disturbed microcirculation and 
alterations in white blood cell rheology may be one mechanism leading to 
vascular complications. Previous studies of white cell deformability in 
diabetic patients have involved filtration of total white cell suspensions 
through Nuclepore filters and increased clogging of the filter, an indirect 
measure of deformability, has been reported by some investigators 
(116,132). However no study has attempted to measure the deformability 
of white cell subpopulations in diabetic patients and therefore we sought to 
determine if deformability of Mononuclear (Monocytes + lymphocytes, MNL) 
and Polymorphonuclear (PMNL) subpopulations was altered in type 2 
(non-insulin-dependent) diabetic patients compared to non-diabetic control 
subjects.
1 12
8.2 Patients
8.2.1 Diabetic patients
19 type 2 (non-insulin dependent) diabetic patients (12 male and 7 female) 
were selected from the outpatient clinic. Mean age was 56 yrs with a range 
of 39-73yrs, and all were free of diabetic complications. 12 patients were 
taking oral hypoglycaemic agents in addition to dietary therapy and 2 
patients were receiving dietary therapy alone. Duration of diabetes in these 
14 patients was 5 yrs (range 6 mths - 11 yrs). The remaining 5 patients 
were newly diagnosed and therefore receiving no treatment.
Mean blood glucose level was 14.3 mmol/l (range 4.0-25.0 mmol/l) and 
glycated haemoglobin 12.9% (range 8.5-17.1%).
8.2.2 Control subjects
The diabetic patients were compared with 19 healthy control subjects who 
were matched for age (mean age 58 years, range 43-73 years) and sex 
distribution (11 male and 8 female).
8.4 Methods
8.4.1 Blood samples
Venous blood was anticoagulated with EDTA (1.5 mg/ml) and 5 mis of 
whole blood was layered on top of 1 mis Ficoll-Hypaque solution 2 which 
was layered on top of 4 mis Ficoll-Hypaque solution 1 to achieve 
separation of the white cell subpopulations (chapter 3.7.2). The Ficoll-
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Hypaque solutions were made within the laboratory. The mixture was 
centrifuged at 200g, 20°C for 40 minutes after which the two layers of white 
cells were harvested and made up to a concentration of 105/l in phosphate 
buffer saline/bovine serum albumin and used immediately.
Filterability of each white cell subpopulation was measured by pressure 
generated (cm H2O) during 6 mins of constant flow of cell suspensions 
(1.5ml/min) through 5pm pores in a polycarbonate membrane (Nuclepore), 
relative to the pressure generated by prefiltration with buffer-albumin alone 
(usually about 1 cm H20). Pressures were analysed at 1 min intervals and 
a time dependent increase in pressure was observed due to progressive 
plugging of pores by slowly-passing white cells (Figure 8.1).
Differential white cell counts were measured by Coulter-S-Counter, 
glycated haemoglobin (HbA1) by agar gel electrophoresis (Corning- 
Glytrac), and blood glucose by the hexokinase method (Hitachi 737, 
Boeringer Mannheim, FRG ).
8.4.2 Statistical methods
Differences in mean values between the groups were calculated by Mann- 
Whitney U-test and correlations by Spearman rank test.
Values are expressed as mean ± SD, or range.
8.5 Results
Relative filtration pressures were significantly higher for MNL compared 
with PMNL in both diabetic patients (6.96 ±2.67 vs 4.24 ± 1.75 cmH20,
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Figure 8.1
Relative filtration pressures (from 1-6 mins) of 
mononuclear and polymorphonuclear cells in 
diabetic and control subjects
p < 0.001) and control subjects ( 7.75 ± 1.62 vs 4.20 ± 0.76 cmH20, p 
<0.001), (Figures 8.1 and 8.2).
There was no significant difference in either MNL or PMNL filtration 
pressures between the diabetic patients or the control subjects at 6 mins 
(6.96 ± 2.67 vs 7.75 ± 1.62 cm H20, p>0.05 and 4.24 ± 1.75 vs 4.20 ± 0.76 
cmH20, p>0.05), (Figure 8.2).
A significant inverse correlation of HbA-| and fasting blood glucose with 
MNL filtration pressure was found (r = -0.74, p<0.001 and r = -0.76, 
p<0.02), and with PMNL filtration pressure (r = -0.71, p<0.001, and r=-0.46, 
p<0.05), (Figure 8.3). No correlations were found between either MNL or 
PMNL filtration pressures and duration of diabetes, but there was a weak 
correlation of age and mononuclear filtration ratio in the population as a 
whole, Table 8.2. The effect of diabetic therapy on white cell deformability 
was not examined due to the imbalance of patients on oral hypoglycaemic 
treatment compared with dietary therapy in the previously diagnosed 
diabetic patients, and there was no association with sex, or smoking in the 
group as a whole, Table 8.3.
The correlation between percentage monocytes for individuals and MNL 
filtration pressures did not reach the conventional level of significance, (r = 
0.40, p>0.05).
8.6 Discussion
Using this improved separation method for white blood cell subpopulations, 
mononuclear cells were found to be significantly less deformable than 
polymorphonuclear cells, a finding that partly reflects the more rigid 
monocytes which form a significant percentage of mononuclear cells,
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Figure 8.2
Final filtration pressures (at 6 mins) for MNL and PMNL 
in diabetic patients compared to control subjects.
Table 8.2
Correlation of mononuclear and polymorphonuclear 
white cell subpopulations with glycaemic control and 
duration of diabetes. (rs values)
mononuclear polymorphonuclear
Fasting blood glucose (mmol/l) -0.76a -0.46b
Glycated haemoglobuin (%) -0.743 -0.71a
Duration of diabetes (yr) -0.06 -0.18
a p <0.001 
b p <0.05
Table 8.3
Effect of gender and smoking on mononuclear and 
polymorphonuclear relative filtration pressures.
mononuclear polymorphonuclear
< Male 7.49±2.42 4.52±1.53Female 7.17±1.93 3.78±0.08
Yes 8.29±2.84 4.52+1.99
Smoking
No 7.09±1.83 3.9510.86<
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Figure 8.3
Correlation of glycated haemoglobin with 
mononuclear and polymorphonuclear filtration 
pressures.
although there was only a poor correlation of filtration pressure with 
percentage monocytes in whole blood (r=0.40). This finding is in 
agreement with the results of previous studies of white cell deformability 
(31,32,233), but in contrast to the two previous filtration studies of white cell 
deformability in diabetic patients (116,132) no differences were found for 
either white cell subpopulation studied between diabetic patients or non­
diabetic control subjects.
When white blood cells become activated they develop protopods: these 
are sheet like projections formed at the cell membrane which are a gelation 
of actin-like and myosin-like proteins. Protopods increase the resistance to 
deformation at the sites where they form (158) and thus a greater filtration 
pressure will be required if white cells become activated.
There was an interesting correlation of filtration pressures with glycaemic 
control in the diabetic patients, particularly with mononuclear cells; well- 
controlled diabetics had less filterable white blood cells than non-diabetics, 
whereas poorly-controlled diabetics had more filterable cells. It is possible 
that the cells become activated during the extraction process, but since 
samples from both groups were analysed simultaneously the same 
degree of activation would be expected in all cells. The more activated the 
cell the greater the pressure required for filtration through micropores, and 
as diabetic patients with the worst glycaemic control had the most easily 
deformed cells it may be that these cells were less able to be activated than 
cells from well-controlled diabetic patients. These findings could have 
implications for other white cell functions such as chemotaxis and 
phagocytosis.
Alterations in microvessel geometry in diabetic patients in vivo (i.e. 
endothelial proliferation and capillary narrowing which are widespread in
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diabetic microvascular disease) will have further effects on leucocyte flow. 
White blood cells being less deformable than red blood cells would be 
expected to have a major effect in regulating red blood cell flow and 
distribution in microvascular disease. In addition, the alterations in the 
vessel wall per se could exert an adverse effect on the white cells by 
increasing the tendency to adhesion. The combination of these effects may 
contribute to tissue hypoxia and therefore end-organ damage in diabetes.
8.7 Summary
This study did not detect any differences in white cell deformability between 
diabetic patients and non-diabetic control subjects, but the significant 
association of filtration pressure of mononuclear and polymorphonuclear 
subpopulations with glycaemic control suggests that uncontrolled diabetes 
may have an effect on white cell function. Further studies of the association 
between white cell deformability and glycaemic control are indicated, using 
techniques that avoid cell activation, and also to examine the relationship of 
diabetic complications to white cell deformability.
It would be of interest to measure white cell deformability in type 1 diabetic 
patients, to investigate the effects of insulin therapy and glycaemic control.
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CHAPTER 9 
DISCUSSION
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Diabetes mellitus is a metabolic disorder characterised by a high level of 
plasma glucose, and is associated with specific microvascular 
complications such as retinopathy and nephropathy. Affected individuals 
have an earlier onset of macrovascular disease, with increased morbidity 
and mortality from large vessel complications. A combination of blood flow 
abnormalities and alterations in vessel geometry probably result in reduced 
perfusion and tissue oxygenation. Increased blood viscosity has been 
demonstrated in diabetes and recently attention has been focussed on the 
contribution of cellular properties to abnormal rheology in diabetic patients. 
Red blood cell rheology has been examined by a variety of methods and 
attempts have been made to correlate this with glycaemic control, with 
treatment and duration of diabetes and with vascular complications. The 
results of many studies have been conflicting but whole blood viscosity 
appears to be increased in diabetes due to an increase in plasma proteins 
which cause an increase in plasma viscosity and red cell aggregation.
Previous methods of measuring red cell aggregation and red cell 
deformability were non-specific and thus unsuitable for assessing diabetic 
patients to confirm the extent of the increase in red cell aggregation or the 
reduction in red cell deformability suggested by viscosity studies. Using the 
new Myrenne red cell aggregometer, increased red cell aggregation has 
been confirmed and for the first time a relationship between aggregation 
and plasma lipoproteins has been demonstrated. A reduction in red cell 
deformability in diabetic patients has also been confirmed using the new 
Carri-Med filtrometer.
The findings in this thesis show rheological differences between type 1 
(insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients: 
red cell deformability was reduced to a greater extent than in type 2 diabetic
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patients, whereas red cell aggregation was further increased in type 2 
diabetics compared with type 1 diabetics. Abnormalities in the red cell 
membrane related to insulin deficiency probably have an important effect 
on red cell deformability and one would expect these to be more 
pronounced in type 1 diabetics. The association of red cell aggregation 
with VLDL, the lipoprotein which is most consistently raised in type 2 
diabetes, may explain the increased aggregation in type 2 compared with 
type 1 diabetics.
Whole blood viscosity was increased in type 2 hypertensive diabetic 
patients, and because viscosity correlates with left ventricular mass (a 
determinant of cardiovascular complications) in non-diabetic hypertensive 
patients, this may help to explain the increased cardiovascular morbidity in 
diabetes. The results of the studies in red cell aggregation reported in type 
2 hypertensive diabetic patients in the thesis also support the role of 
increased viscosity contributing to cardiovascular problems in this 
subgroup of hypertensive diabetic patients. It would be relevant to 
investigate in future studies the relationship between blood viscosity and 
cardiac hypertrophy in diabetic patients. Altered lipids and lipoproteins in 
type 2 patients may partly explain the abnormal rheology and the cause of 
the earlier onset of large vessel disease in diabetes as a whole.
Microvascular complications tend to be more prevalent in type 1 diabetic 
patients due to their longer duration of diabetes, and increased blood 
viscosity has been demonstrated in type 1 diabetics with microvascular 
disease in the viscosity studies described here. This finding is supported 
by the increased red cell aggregation which was found in type 1 diabetics 
with proliferative retinopathy. Alterations of red cell deformability in either 
microvascular or macrovascular disease have not been demonstrated in
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any of the studies undertaken. However a reduction in red cell 
deformability although not related to specific problems in diabetes could in 
conjunction with microvascular abnormalities reduce blood flow to tissues 
and result in ischaemic damage to the retina, kidney, nerves or heart. The 
association between rheology and macrovascular complications such as 
ischaemic heart disease, peripheral vascular disease and cerebrovascular 
disease needs to be established in diabetic patients.
White cell deformability is an important determinant of blood flow in the 
microcirculation and because red cell deformability is reduced in diabetes, 
one may speculate that deformability of white cells would also be reduced. 
The preliminary study described here found no difference in white cell 
deformability between diabetic patients and healthy age matched controls, 
but only a small group of type 2 diabetics was examined. The technique 
therefore needs to be evaluated in a much larger sample group which 
should include both type 1 and type 2 diabetic patients, and this would 
allow any association of white cell deformability and vascular complications 
to be investigated.
A microvascular aetiology in conjunction with metabolic dysfunction is likely 
in diabetic peripheral neuropathy, but although blood rheology is 
undoubtably abnormal in affected diabetics, it appears not to be further 
increased in diabetic patients with neuropathy compared with those who 
have no evidence of neuropathy but are matched for other microvascular 
complications. Disturbance in microvessel structure may be a more 
important determinant of vascular related damage to peripheral nerves in 
diabetic patients.
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This thesis presents evidence that diabetes mellitus is associated with 
abnormal blood rheology, and that there are differences in the determinants 
of blood viscosity between type 1 and type 2 diabetic patients. There was a 
measurable association between rheology and m icrovascular 
complications in type 1 diabetics and between rheology and hypertension 
in type 2 diabetics. The data was all cross-sectional, and to establish the 
true role of blood rheology in the complications of diabetes mellitus, it 
would be necessary to perform longterm prospective studies. Further 
research in the future is indicated to assess blood viscosity and red cell 
aggregation in particular, in hyperlipidaemic individuals with and without 
diabetes and to assess the effects of lipid-lowering agents on rheology. In 
hypertensive diabetics, early intervention with antihypertensive agents such 
as vasodilators may reduce blood viscosity and could prevent cardiac 
hypertrophy. The effect of antihypertensive agents on rheology therefore 
requires to be established.
Therapeutic agents which improve red cell deformability may have 
beneficial effects in diabetic patients, but they would require evaluation 
over a prolonged period of time to assess their potential benefits in vascular 
complications.
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